Introduction {#s1}
============

Facioscapulohumeral muscular dystrophy (FSHD) is a prevalent myopathy, affecting 12/100,000 people ([@bib23]). Although clinical severity is highly variable, skeletal muscle weakness often appears first in the facial and shoulder girdle muscles, with muscles of the trunk and lower extremities becoming affected as the disease progresses. Distinctive features of FSHD include asymmetric skeletal muscle wasting and scapular winging ([@bib89]). Analysis of myoblasts from FSHD patients has revealed direct functional impairments, including increased susceptibility to oxidative stress ([@bib100], [@bib101]; [@bib14]; [@bib58]; [@bib7]), up-regulation of apoptotic markers ([@bib100], [@bib101]; [@bib81]; [@bib95]; [@bib50]) and repression of *MYOD* and MYOD-target genes ([@bib101]; [@bib14]). Additionally, myogenic differentiation results in myotubes with either an atrophic, or hypertrophic and highly disorganised morphology ([@bib7]; [@bib95]; [@bib87]; [@bib4]). Defects in myoblast function are likely to result in impaired muscle maintenance, directly contributing to clinical symptoms ([@bib63]).

FSHD is divided into two clinically indistinguishable disorders. FSHD1 (1A) (OMIM \#158900) is associated with the contraction of a macrosatellite repeat named D4Z4 in the subtelomeric region 4q35 ([@bib89]; [@bib94]). Embedded within each 3.3 kb D4Z4 repeat unit is an open reading frame (ORF) for *Double homeodomain protein 4 (DUX4*), an intron-less retrogene ([@bib24]; [@bib28]). Contraction of D4Z4 units to between 1--10 is associated with de-repression of chromatin ([@bib94]; [@bib113]; [@bib22]). If this occurs on a permissive chromosomal 4qA haplotype containing a polyadenylation site within the flanking pLAM region, *DUX4* mRNA transcript from the distal D4Z4 repeat is stabilised and DUX4 protein translated ([@bib24]; [@bib53]; [@bib85]). In the rarer FSHD2 (1B) (OMIM \#158901), de-repression of the D4Z4 macrosatellite occurs despite the presence of \>11 D4Z4 repeats, but still requires the permissive 4qA haplotype containing the polyadenylation signal ([@bib22], [@bib21]). FSHD2 has recently been linked to mutations in the *Structural maintenance of chromosomes flexible hinge domain containing* 1 (*SMCHD1*) gene, encoding a protein involved in DNA methylation ([@bib52]). Recently, mutations in *DNA methyltransferase 3B (DNMT3B*) have also been implicated in perturbed epigenetic regulation in FSHD ([@bib93]). Taken together, the consensus is that aberrant DUX4 expression underlies pathogenesis in both FSHD1 and FSHD2 ([@bib88]).

Two main *DUX4* mRNA transcripts can be derived from the ORF in a D4Z4 repeat: *DUX4-fl* (full length) mainly expressed in germline cells, and the alternatively spliced *DUX4-s* (short) transcript expressed in some somatic cells. FSHD skeletal muscle expresses *DUX4-fl* whereas this transcript is not usually found in healthy control muscle ([@bib85]), although very low levels have been reported in some studies ([@bib40]; [@bib86]). Expression of DUX4 in myoblasts recapitulates the pathogenic phenotype of myoblasts from FSHD patients ([@bib95]; [@bib108]; [@bib60]; [@bib11]; [@bib47]; [@bib30]; [@bib10]; [@bib48]; [@bib97]; [@bib29]; [@bib6]). Indeed, suppression of *DUX4* expression using siRNA or anti-sense oligonucleotides rescues the atrophic phenotype of FSHD myotubes in vitro ([@bib95]). DUX4 is a potent transcription factor and analysis of DUX4-expressing myoblasts has revealed that major transcriptional pathways such as cell cycle regulation, glutathione redox metabolism, myogenic differentiation and Wnt signalling are disrupted ([@bib11]; [@bib30]; [@bib6]). In addition, many germline and neural genes are upregulated ([@bib6]; [@bib19]). However, DUX4 is at very low levels in FSHD biopsies ([@bib86]). Despite this, we, and others, have shown that the transcriptional landscape of genes altered by DUX4 is much more prominent in FSHD patient-derived material ([@bib108]; [@bib6]). Therefore, identification of DUX4-induced pathways that contribute to pathology in FSHD and are targetable with drugs provides a useful route for potential FSHD-specific therapies. We have focussed on the effects of DUX4 on myoblasts, to identify approaches to improve muscle repair and regeneration.

At present, there is no single mammalian animal model that encompasses the genetic and pathophysiological spectrum of FSHD ([@bib51]). To model FSHD, we have used retroviral-mediated expression of DUX4, in conjunction with constitutively active and dominant-negative versions, in primary murine satellite cells cultured ex vivo. Comparing gene expression data from DUX4-expressing murine satellite cell-derived myoblasts to a meta-analysis of published microarrays from FSHD patient biopsies and primary cultures ([@bib6]), we revealed a significant overlap between DUX4-expressing murine satellite cell-derived myoblasts and human FSHD muscle ([@bib46]).

We found that the receptor tyrosine kinase (RTK) *Rearranged during transfection (RET*) is up-regulated in DUX4-expressing myoblasts ([@bib6]; [@bib19]). *RET* is a transmembrane RTK containing 4 cadherin-like repeats, a cysteine-rich area, a calcium-binding site on the extracellular region and several intracellular tyrosine kinase domains ([@bib82]; [@bib2]). There are two main *RET* isoforms; *RET9* and *RET51*, alternatively spliced in the 3' region, resulting in an additional tyrosine at Y1096 on RET51 ([@bib38]). These two main *RET* isoforms are differentially expressed, regulated and have diverse roles in development and tissue homeostasis ([@bib109]; [@bib92]; [@bib77]; [@bib39]).

RET is activated by the secreted Glial cell-derived neurotrophic factor (GDNF) family ligands (GFL): GDNF, neurturin (NRTN), artemin (ARTN) and persephin (PSPN). GFLs bind with high affinity to one of four glycosylphosphatidylinositol (GPI)-anchored co-receptors of the GDNF Family Receptor (GFRα) family. GFL:GFRα complexes then recruit two RET molecules, triggering RET dimerisation and trans-phosphorylation of the intracellular region of both molecules. This leads to recruitment of adaptor proteins and activation of downstream signalling cascades such as MAPK, PI3/AKT, JAK/STAT, JNK, ERK5, SRC and PLCγ ([@bib82]; [@bib2]; [@bib79]; [@bib66]). RET9 and RET51 activate PI3K/AKT and ERK signalling with different dynamics and have distinct abilities to recruit Src or Frs2, suggesting differential activation of downstream targets by the two main RET isoforms ([@bib92]; [@bib37]; [@bib8]).

Coordinated RET signalling is crucial for development of multiple tissues, including many neuronal cell types, kidneys and the thyroid gland ([@bib79]; [@bib5]). Indeed, RET knockout mice can be embryonic lethal with a wide range of organ defects ([@bib39]; [@bib83]; [@bib20]). RET signalling has also been shown to regulate spermatogonial and haematopoietic stem cell function ([@bib68]; [@bib27]). Dysregulated RET signalling is associated with disease: inactivating mutations of *RET* lead to a form of neurocristopathy called Hirschsprung's disease ([@bib3]), whereas mutations of *RET* resulting in constitutively active isoforms are associated with several forms of inherited and somatic cancers ([@bib5]; [@bib9]). For example, mutations at codon 634 of *RET* are found in approximately 84% of multiple endocrine neoplasia (MEN2A) patients ([@bib82]; [@bib20]; [@bib65]).

Studies detailing expression of *Ret*, the GFL's and GFRα's in developing or adult rat, mouse and human skeletal muscle report expression of at least some RET signalling components, predominantly during development e.g. ([@bib102]; [@bib69]; [@bib80]; [@bib55]; [@bib106]; [@bib59]; [@bib32]; [@bib107]). Interestingly, *Ret* and *Gdnf* mRNA transcripts have been shown in mesenchymal cells of the second branchial arch in E9-9.5 mouse embryos ([@bib32]; [@bib67]), from which some facial muscles develop. We recently reported that *ret* is important for skeletal muscle development in zebrafish, where ret-gfrα3*-*artemin signalling is required to regulate myogenic differentiation in a subset of muscle precursors deriving from the first and second brachial arches ([@bib44]).

Here we show that Ret is a novel mediator of satellite cell function, contributing to the regulation of proliferation and initiation of myogenic differentiation. Critically, DUX4-mediated Ret signalling is pathogenic to satellite cells, contributing to impaired differentiation. However, blocking DUX4-mediated Ret signalling using siRNA or the RTK inhibitor Sunitinib, leads to an increase in the myogenic capacity of DUX4-expressing murine satellite cells. Importantly, Sunitinib also improves proliferation and differentiation in FSHD patient-derived myoblasts both *in vitro*, and *in vivo* after grafting into regenerating muscle in mice. These observations highlight using RTK inhibitors as a potential therapeutic strategy for FSHD.

Results {#s2}
=======

Ret and Ret co-receptors are expressed in murine myoblasts {#s2-1}
----------------------------------------------------------

To determine whether *Ret* is expressed in murine satellite cells, myofibres with their associated satellite cells were isolated and either fixed immediately (T0), or cultured for 24 (T24) or 72 (T72) hours. Co-immunolabelling to detect Pax7 and Ret51 of fixed myofibres at T0 and T24 revealed that Ret51 was barely detectable in quiescent satellite cells, but expression increased after 24 hr of activation ([Figure 1A and B](#fig1){ref-type="fig"}). This correlated with an increase in phospho-Ret Tyr1062 immunolabelling, indicative of active Ret signalling. By T72, a proportion of satellite cell-derived myoblasts stop expressing Pax7 and commit to myogenic differentiation, expressing Myogenin ([@bib111]). Ret51 was found in both Myogenin-negative uncommitted myoblasts and Myogenin-positive differentiating myoblasts ([Figure 1C](#fig1){ref-type="fig"}).10.7554/eLife.11405.002Figure 1.Expression dynamics of *Ret* and *Gfrα* co-receptors during myogenic progression in murine satellite cell-derived myoblasts.Co-immunolabelling of Ret in satellite cells associated with isolated myofibres. (**A**--**C**) Expression of Ret51 and phosphorylated (Y1062) Ret (pRet) in quiescent (T0) Pax7-positive satellite cells (**A**), Pax7-positive satellite cells cultured for 24 hr (T24) (**B**) and expression of Ret51 in differentiation-committed Myogenin-positive and Myogenin-negative satellite cells (**C**). DAPI (blue) was used as a nuclear counterstain. (**D**--**G**) Relative expression dynamics of *Ret* and its co-receptors *Gfrα1, Gfrα2* and *Gfrα4* during satellite cell proliferation (prolif.) and through differentiation (DM 6--48 hr), normalised to *Tbp*. Data is mean ± SEM from 3 independent experiments using 3 mice. An asterisk denotes significant difference (p\<0.05) from the expression level in proliferating cells, as determined using a paired Student's *t*-test. Scale bar equals 50 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.002](10.7554/eLife.11405.002)

Next, the expression of *Ret* and its *Gfrα* co-receptors was profiled during myogenic progression. Satellite cell-derived myoblasts were isolated from three 8-week old C57BL/10 mice and mRNA harvested from plated expanded cultures in proliferation medium or after 6, 12, 24 or 48 hr in differentiation medium ([Figure 1D--G](#fig1){ref-type="fig"}). *Ret, Gfrα1, Gfrα2* and *Gfrα4,* but not *Gfrα3,* were robustly expressed in these myoblast cultures. Expression of *Ret* decreased during myoblast differentiation, whereas *Gfrα1, Gfrα2* and *Gfrα4* increased upon differentiation.

RET is expressed in human myoblasts {#s2-2}
-----------------------------------

We next investigated expression of *RET* in human primary satellite cell-derived myoblasts ([Figure 2](#fig2){ref-type="fig"}). Primary myoblasts were isolated from vastus lateralis of three 19-year old females and the CD56+ fraction purified using magnetic-activated cell sorting ([@bib1]). CD56+ satellite cell-derived myoblasts from each individual were cultured in proliferation medium or in differentiation medium for 1, 2, 3 or 4 days. Cultures were fixed and immunolabelled to confirm differentiation ([Figure 2A](#fig2){ref-type="fig"}). RNA was extracted from sister cultures for RT-qPCR analysis, which revealed that *RET* was detectable at low levels in proliferating and differentiating human primary myoblasts ([Figure 2B](#fig2){ref-type="fig"}), with control genes *CYCLIN D1, MYOD, MYOG* and *MYHC* used to confirm proliferation/differentiation status ([Figure 2C--F](#fig2){ref-type="fig"}).10.7554/eLife.11405.003Figure 2.RET is expressed in proliferating and differentiating primary human satellite cell-derived myoblasts.(**A**) Immunolabelling of primary human myoblasts extracted from the *vastus lateralis* of 3 individuals (Exp. 1 to 3) co-immunolabelled for Desmin (red -- cytoplasmic), Ki67 (mauve -- nuclear), Myogenin (green -- nuclear), MyHC (grey -- cytoplasmic) and counterstained with DAPI (blue -- nuclear). (**B**--**F**) Relative expression of (**B**) *RET*, (**C**) *Cyclin D1*, (**D**) *MYOD*, (**E**) *MYOG* and (**F**) *MYHC* transcription during proliferation (Prolif.) and after 1, 2, 3 and 4 days in differentiation medium (DM1-4), measured by RT-qPCR and normalised to *RPLPO* housekeeping gene. Data is mean ± SEM where an asterisk denotes significant difference (p\<0.05) from the expression level in proliferating cells, as determined using a paired Student's *t*-test. Scale bar equals 50 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.003](10.7554/eLife.11405.003)

Ret is required for satellite cell proliferation {#s2-3}
------------------------------------------------

To test whether satellite cells require *Ret* for normal function, we performed siRNA-mediated knockdown. Expanded murine satellite cell cultures were transfected with 20 nM of *Ret* siRNA directed at both *Ret9* and *Ret51* isoforms, or a scrambled-sequence control siRNA, for 48 hr. Knockdown was assessed by RT-qPCR, with a mean knockdown efficiency of \~80% achieved. siRNA-treated satellite cell-derived myoblasts were pulsed for two hours with the thymidine analogue 5-Ethynyl-2\'-deoxyuridine (EdU), which incorporates into DNA during S phase of the cell cycle and can be used to measure relative proliferation rate, and then immunolabelled for Pax7 ([Figure 3A](#fig3){ref-type="fig"}). Knockdown of *Ret* significantly reduced the proportion of myoblasts that had incorporated EdU, from a mean ± SEM of 44.0 ± 4.5% to 28.0 ± 3.2% ([Figure 3B](#fig3){ref-type="fig"}). Sister cultures of siRNA-treated myoblasts were then co-immunostained with phosphorylated-histone H1 and phosphorylated-histone H3 protein to identify specific stages of the cell cycle ([@bib57]; [@bib45]; [@bib34]). This confirmed that *Ret* knockdown led to decreased proliferation, with significantly fewer cells in S and G1 phases ([Figure 3C](#fig3){ref-type="fig"}).10.7554/eLife.11405.004Figure 3.Knockdown of *Ret* enhances myogenic differentiation of satellite cells.(**A**) Satellite cell-derived myoblasts transfected with control or *Ret* siRNA for 48 hr and pulsed for 2 hr with EdU (red) to measure the proliferation rate, and immunolabelled for Pax7 (green) and counterstained with DAPI (blue), quantified in (**B** and **D**). (**C**) Quantification of satellite cell-derived myoblasts transfected with control or *Ret* siRNA and labelled with phospho-Histone H1/H3. Cells were grouped according to their cell cycle stage. (**E**--**G**) RT-qPCR analysis of the relative expression of *Pax7, MyoD* and *Myf5* in satellite cell-derived myoblasts transfected with control or Ret siRNA for 48 hr, with expression normalised to *Gapdh*. (**H** and **I**) Satellite cell-derived myoblasts transfected with *Ret* or control siRNA and incubated in differentiation medium for 48 hr, immunolabelled with Myogenin (red) and counterstained with DAPI (blue) (**H**) or Myosin Heavy Chain (MyHC - green) and counterstained with DAPI (blue) (**I**), quantified in (**J**--**L**). (**L**) Quantification of the relative proportion of small (2 \> 4 nuclei), medium (5 \> 9 nuclei), large (10 \> 24 nuclei) and very large (25+ nuclei) myotubes. Data is mean ± SEM from 3--4 mice in each case, where statistical difference (p*\<*0.05) from control siRNA was determined using a paired Student's *t*-test and denoted by an asterisk. Scale bars equal 50 µm (**A**) and 200 µm (**H** and **I**).**DOI:** [http://dx.doi.org/10.7554/eLife.11405.004](10.7554/eLife.11405.004)

SiRNA-mediated knockdown of *Ret* was also associated with a small decrease in the proportion of myoblasts containing Pax7 protein ([Figure 3D](#fig3){ref-type="fig"}). The reduced number of proliferating, Pax7 expressing myoblasts when *Ret* is knocked down suggests that *Ret* contributes to maintaining myoblasts in an undifferentiated state. We also observed a reduction of *Pax7* expression in response to *Ret* knockdown ([Figure 3E](#fig3){ref-type="fig"}). Although *Pax7* is genetically upstream of *MyoD* and *Myf5* ([@bib76]), *Ret* knockdown did not alter *MyoD* ([Figure 3F](#fig3){ref-type="fig"}) or *Myf5* expression ([Figure 3G](#fig3){ref-type="fig"}).

Knockdown of Ret enhances myogenic differentiation of satellite cell-derived myoblasts {#s2-4}
--------------------------------------------------------------------------------------

Satellite cell-derived myoblasts treated with *Ret* siRNA had reduced *Pax7* expression and proliferation rate, implying that they may be differentiating prematurely. To investigate this, cultures were treated with control or *Ret* siRNA, plated at high density and incubated in differentiation medium for 48 hr, before immunolabelling for Myogenin and Myosin Heavy Chain (MyHC) ([Figure 3H and I](#fig3){ref-type="fig"}). The proportion of Myogenin-positive nuclei was significantly increased in *Ret* siRNA-treated cultures relative to control siRNA-treated cells (85.4 ± 4.0% versus 69.1 ± 4.0%) ([Figure 3J](#fig3){ref-type="fig"}). In contrast, the proportion of nuclei in MyHC-expressing multinucleate myotubes (presented as the fusion index: the proportion of nuclei in myotubes of 2 or more nuclei, [Figure 3K](#fig3){ref-type="fig"}) was unaltered in control cells (60.0 ± 3.0%) compared to cells treated with *Ret* siRNA (62.7 ± 2.2%). To determine if the extent of myoblast fusion was affected, myotubes were classified by the number of nuclei per myotube (small (2\>4), medium (5\>9), large (10\>24) and extra-large (25+). *Ret* siRNA knockdown led to more large myotubes (10.7 ± 1.9%) relative to control (5.4 ± 1.8%, [Figure 3L](#fig3){ref-type="fig"}).

Knockdown of Gfrα2 or Gfrα4 recapitulates aspects of Ret knockdown {#s2-5}
------------------------------------------------------------------

To determine which Gfrα co-receptors expressed in satellite cell-derived myoblasts may activate Ret signalling, myoblasts were transfected with siRNA against Gfrα1, Gfrα2, Gfrα4, or scrambled control siRNA, for 48 hr, before cells were immunolabelled for phospho-Histone H1/H3, Pax7, Myogenin and MyHC ([Figure 4A--D](#fig4){ref-type="fig"}). Phospho-Histone H1 and H3 immunostaining revealed that knockdown of Gfrα1, Gfrα2 and Gfrα4 were associated with fewer cells in the active stages of the cell cycle ([Figure 4A](#fig4){ref-type="fig"}). As with *Ret* siRNA, knockdown of Gfrα4 (but not Gfrα1 or Gfrα2) was associated with fewer Pax7-containing satellite cell-derived myoblasts in proliferation medium, from 82.8 ± 2.0% in controls to 69.8 ± 4.3% in cells with siRNA to Gfrα4 ([Figure 4B](#fig4){ref-type="fig"}). After 48 hr in differentiation medium, the proportion of Myogenin-positive nuclei was significantly increased following knockdown of Gfrα2 and Gfrα4 ([Figure 4C](#fig4){ref-type="fig"}). Additionally, knockdown of Gfrα4 significantly increased the fusion index (from 39.3 ± 3.1% in the control sample to 46.8 ± 3.0% with Gfrα4 siRNA ([Figure 4D](#fig4){ref-type="fig"}). Taken together, knockdown of Gfrα co-receptors recapitulated aspects of *Ret* knockdown, indicating that multiple co-receptors may signal through Ret in muscle stem cells.10.7554/eLife.11405.005Figure 4.Gfrα1, Gfrα2 and Gfrα4 affect myoblast proliferation and myogenic differentiation.(**A**--**D**) Quantification of satellite cell-derived myoblasts transfected with control or Gfrα1, Gfrα2 or Gfrα4 siRNA for 48 hr in proliferation medium (**A** and **B**) or differentiation medium (**C** and **D**). Immunolabelling of cells was performed to quantify the proportion in the cell cycle using anti-phospho-Histone H1 and H3 (**A**), the proportion containing immunosignal for Pax7 (**B**), Myogenin (**C**) and the proportion of nuclei in multinucleated myotubes (fusion index) (**D**). Data is mean ± SEM from 3 independent experiments using 3 mice, where statistical difference (p*\<*0.05) from control siRNA was assessed using a paired Student's *t*-test and denoted by an asterisk.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.005](10.7554/eLife.11405.005)

Active Ret signalling drives myoblast proliferation but does not affect differentiation {#s2-6}
---------------------------------------------------------------------------------------

We next used retroviral-mediated constitutive expression to examine the effects of increased *RET* expression on satellite cell proliferation and differentiation. Human *RET9* and *RET51*, together with constitutively active (CA) *RET9* and *CA RET51* (containing a Cys634Lys mutation causing ligand-independent dimerisation of the RET receptor \[[@bib65]\]), were cloned into a retroviral backbone containing an *IRES-eGFP* to identify transduced cells. These retroviral constructs encoded RET protein of 170kDa as expected ([Figure 5A](#fig5){ref-type="fig"}) and human *RET* mRNA was present 48 hr after transduction of mouse myoblasts ([Figure 5B](#fig5){ref-type="fig"}). Expression of endogenous murine *Ret* was unaltered by human *RET* expression ([Figure 5C](#fig5){ref-type="fig"}).10.7554/eLife.11405.006Figure 5.Active RET signalling drives satellite cell-derived myoblast proliferation.(**A**) Immunoblot analysis of the RET protein in HEK 293T cells transfected with plasmids encoding human *RET 9, RET 51, CA RET9* and *CA RET51* for 24 hr. Equal quantities of total protein extracts were run on 4--20% gradient PAGE-SDS gels, transferred and blotted with antibodies recognising both RET isoforms (pan-RET, top band and RET51, middle band). Bands of 170 kDa were detected in HEK 293T cells transfected with *RET*-encoding plasmids, but not in cells transfected with control plasmid. β-Tubulin was used as a loading control. (**B**--**K**) Satellite cell-derived myoblasts transduced with control retrovirus encoding *eGFP* alone, or retroviruses encoding *RET 9, RET 51, CA RET9* or *CA RET51*, together with GFP. mRNA was prepared (**B**--**C**) or myoblasts immunolabelled for eGFP (to identify transduced cells) and assayed for EdU incorporation (**D** and **E**) or co-immunolabelled for eGFP and either Pax7 (**F** and **G**), Myogenin (**H** and **I**) or MyHC (**J**--**K**). (**B**--**C**) RT-qPCR to measure expression of the human versions of RET (**B**) and endogenous murine *Ret* (**C**). (**D** and **E**) Quantification of the proportion of eGFP+ satellite cell-derived myoblasts incorporating EdU after a 2 hr exposure. (**F**--**K**) Quantification of the proportion of eGFP-expressing satellite cell-derived myoblasts containing Pax7 (**F** and **G**), Myogenin (**H** and **I**) and the fusion index (**J** and **K**). RT-qPCR and quantification of immunolabelling is presented as mean ± SEM from 3 or 4 independent experiments using 3--4 mice, where statistical difference (p*\<*0.05) to transduction with control retrovirus was assessed using a paired Student's *t*-test and denoted by an asterisk. Scale bar equals 50 µm (**D** and **F**) or 200 µm (**H** and **J**).**DOI:** [http://dx.doi.org/10.7554/eLife.11405.006](10.7554/eLife.11405.006)

To ascertain whether RET affects proliferation rate, myoblasts were infected with retroviruses encoding the RET isoforms and pulsed with EdU for 2 hr in proliferation medium. Constitutive expression of either wild-type RET9 or RET51 did not alter the proportion of eGFP+/EdU+ myoblasts compared to transduction with control retrovirus. However, the CA RET constructs significantly increased proliferation rate, with EdU incorporation rising from 47.6 ± 0.8% in controls to 56.9 ± 1.8% (CA RET9) and 59.2 ± 1.7% (CA RET51) ([Figure 5D and E](#fig5){ref-type="fig"}). RET did not alter the overall proportion of Pax7-containing cells ([Figure 5F and G](#fig5){ref-type="fig"}).

To determine whether constitutive expression of RET affects myogenic differentiation, we analysed expression of Myogenin and MyHC in myoblasts cultured in differentiation medium ([Figure 5H--K](#fig5){ref-type="fig"}). After 24 hr of differentiation, CA RET51 reduced the proportion of myoblasts that contained Myogenin (49.5 ± 1.2%) relative to controls (58.9 ± 3.1%), but by 48 hr there was no longer any difference ([Figure 5H and I](#fig5){ref-type="fig"}). At this stage, there was no alteration in fusion index ([Figure 5J and K](#fig5){ref-type="fig"}).

DUX4 induces Ret in satellite cell-derived myoblasts {#s2-7}
----------------------------------------------------

To identify genes affected by DUX4 expression, we analysed our microarray data (GSE77100, <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77100>), which measured transcriptional changes in murine satellite cell-derived myoblasts 20 hr after transduction with retroviruses encoding DUX4, DUX4c (a truncated homologue of DUX4 containing the same homeodomains, encoded by a D4Z4 unit centromeric to the macrosatellite \[[@bib12]\]), truncated (tMALDUX4), constitutively active (tMALDUX4-VP16) or dominant-negative (tMALDUX4-ERD) DUX4 constructs ([@bib6]). *Ret* expression was increased 3.45-fold in DUX4-expressing satellite cell-derived myoblasts, and approximately 2 fold by either tMALDUX4-VP16 or tMALDUX4-ERD, relative to controls. Expression of Ret co-receptors *Gfrα2, Gfrα3* and *Gfrα4* were unaltered, although *Gfrα1* expression was reduced 0.57-fold by DUX4 ([Figure 6A](#fig6){ref-type="fig"}). Expression of DUX4c did not alter *Ret* or *Gfrα* co-receptor expression ([Figure 6A](#fig6){ref-type="fig"}).10.7554/eLife.11405.007Figure 6.DUX4 expression induces *Ret* in satellite cell-derived myoblasts.(**A**) Microarray data of expression levels of Ret and Ret co-receptors Gfrα1--4 in murine satellite cell-derived myoblasts transduced for 20 hr with retroviruses encoding either DUX4, truncated DUX4 (tMALDUX4), constitutively active DUX4 (tMALDUX4-VP16), dominant-negative DUX4 (tMALDUX4-ERD) or DUX4c ([@bib6]). Red highlights increased expression while green highlights reduced expression (fold change) compared to transduction with control retrovirus. (**B**--**D**) Quantification of total *Ret, Ret9* and *Ret51* expression by RT-qPCR in satellite cell-derived myoblasts transduced with DUX4, DUX4c or control retroviruses at 24 and 48 hr post-infection. (**E**--**F**) *Ret* expression in iC2C12-DUX4 myoblasts (**E**) and iC2C12-DUX4c myoblasts (**F**) following 200ng/ml doxycycline (DOX) induction. (**G**) Satellite cell-derived myoblasts transduced with DUX4-encoding retrovirus for 24 hr and immunolabelled for eGFP (green) to identify transduced cells and anti-RET51 (red), with a DAPI counterstain (blue). Data is mean ± SEM from 3 independent experiments using 3 mice for (**B**--**D**) where statistical difference (p*\<*0.05) from transduction with control retrovirus was assessed using a paired Student's *t*-test and denoted by an asterisk. For **E** and **F** , unpaired Student\'s t-tests were used to assess significance (p*\<*0.05) compared to uninduced cells at each time point. UI = un-induced, I = induced by doxycycline. Scale bar equals 100 µm (**G**).**DOI:** [http://dx.doi.org/10.7554/eLife.11405.007](10.7554/eLife.11405.007)

To confirm that *Ret* is a downstream DUX4 target gene in satellite cell-derived myoblasts, we transduced myoblasts with retroviral constructs encoding DUX4 or DUX4c. There was a trend for DUX4 to increase *Ret* transcription after 24 hr (p=0.052), which increased significantly (97.5-fold) after 48 hr, relative to control plasmid-transduced cells ([Figure 6B](#fig6){ref-type="fig"}). Using isoform-specific primers, we found that DUX4 increased expression of *Ret9* (150-fold) more than *Ret51* (15.8-fold) after 48 hr ([Figure 6C and D](#fig6){ref-type="fig"}). Using inducible iC2C12-DUX4 and iC2C12-DUX4c myoblasts ([@bib19]), expression of *Ret* was significantly increased after 12 hr of induction with 200ng/ml doxycycline in the iC2C12-DUX4 line, compared to un-induced myoblasts, and maintained at elevated levels at 24 and 48 hr of induction ([Figure 6E](#fig6){ref-type="fig"}). Induction of DUX4c in the iC2C12-DUX4c line did not generally alter *Ret* expression ([Figure 6F](#fig6){ref-type="fig"}). DUX4 activation of *Ret* also led to the detection of membrane-located Ret protein, as revealed by immunolabelling with an antibody to Ret51 in DUX4-infected myoblasts ([Figure 6G](#fig6){ref-type="fig"}).

Down-regulation of Ret rescues DUX4-mediated inhibition of myogenic differentiation {#s2-8}
-----------------------------------------------------------------------------------

Our findings that *Ret* is a DUX4 target that influences satellite cell proliferation and differentiation, make it a good candidate to test inhibitors for ameliorating DUX4-induced pathogenesis. A major feature of DUX4 expression in myoblasts is the induction of p53-dependent apoptosis ([@bib11]; [@bib48]; [@bib97]; [@bib103]). Interestingly, Ret is a dependence receptor, triggering apoptosis in the absence of its ligands ([@bib33]). Therefore, one might hypothesise that DUX4-mediated up-regulation of *Ret* in the absence of sufficient GFLs could lead to cell death.

RT-qPCR revealed that both *Ret* isoforms were expressed in primary murine satellite cells ([Figure 7A](#fig7){ref-type="fig"}). To test whether over-expression of *RET* isoforms can promote cell death, satellite cell-derived myoblasts were transfected, rather than transduced, with RET plasmids, to induce high levels of expression. Then the relative levels of active caspase 3/7 were measured in proliferating myoblasts using a luminescent assay. However, over-expression of either RET isoform significantly reduced caspase 3/7 release, implying that DUX4-mediated up-regulation of RET does not contribute to the apoptotic phenotype ([Figure 7B](#fig7){ref-type="fig"}).10.7554/eLife.11405.008Figure 7.Knockdown of *Ret* rescues DUX4-mediated inhibition of myogenic differentiation.(**A**) Relative expression of *Ret9* and *Ret51* in myoblasts infected with control retrovirus after 24 hr. (**B**) Quantification of a caspase 3/7 Glo assay to measure apoptosis in satellite cell-derived myoblasts transfected with control plasmid encoding *GFP*, or *RET 9, RET 51, CA RET9* or *CA RET51* encoding plasmids. (**C**--**D**) Quantification of proliferation by EdU incorporation (**C**) and *Pax7* expression (**D**) in *eGFP*-expressing myoblasts transduced with control or DUX4-encoding retrovirus and then transfected with control or *Ret* siRNA for 48 hr. Data is mean ± SEM from 3 mice where statistical difference (p*\<*0.05) to control plasmid (**B**) or control retrovirus + control siRNA (**C** and **D**) was assessed using a paired Student's *t*-test and denoted by an asterisk. Bar is comparison between indicated conditions, where N.S. denotes non-significant difference. (**E**) Immunolabelling of satellite cell-derived myoblasts transduced with control or *DUX4*-encoding retrovirus and transfected with control or *Ret* siRNA following culture for 24 hr in differentiation medium. Transduced cells were detected by immunolabelling for eGFP and examined for MyHC to identify terminally differentiated myotubes. (**F**) The fusion index was calculated for eGFP-positive cells expressing control or *DUX4*-encoding retrovirus and transfected with control or *Ret* siRNA. Bar represents statistical test significance, where an asterisk denotes p\<0.01. (**G**) Plot of probability that a cell has MyHC immunoreactivity derived from binomial models ([Figure 7---source data 1](#SD1-data){ref-type="supplementary-material"}). Error bars represent 95% confidence intervals. Four replicates were counted for each condition and repeated using 3 mice. Scale bar equals 200 µm (**E**).**DOI:** [http://dx.doi.org/10.7554/eLife.11405.008](10.7554/eLife.11405.008)10.7554/eLife.11405.009Figure 7---source data 1.Maximum likelihood parameters for a logistic model containing an interaction term, and a random effect term describing the probability of a nucleus being present in a MyHC+ cell.(**a**) Maximum likelihood parameters for a logistic model containing an interaction term, and a random effect term (the mouse) describing the probability of a nucleus being present in a MyHC+ cells. (**b**) Corresponding ratios computed from the model, for all 4 tested conditions with the ratio representing the probability of a GFP+ cell expressing MyHC. In all condition but the control (Intercept), the error contribution of the baseline (Intercept) has been omitted when computing the confidence intervals (C.I.). *y* represents the log-of-odds of the fusion index. µ represents the intercept parameter (representing the control: MIG control retrovirus, control siRNA), *β* are the parameters representing the effects of each treatment, or the interaction as specified and δ indicates whether the effect is present or absent.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.009](10.7554/eLife.11405.009)

DUX4 also suppresses *Pax7* and myogenic regulatory factor (MRF) gene expression and inhibits proliferation and myogenic differentiation ([@bib60]; [@bib11]; [@bib47]; [@bib104]). To determine if we could rescue DUX4-induced pathology by inhibiting Ret signalling, we measured the effects of siRNA-mediated inhibition of *Ret* in DUX4-expressing murine satellite cell-derived myoblasts. Myoblasts transduced with control or DUX4 encoding retrovirus were additionally transfected with 20 nM control or *Ret* siRNA for 48 hr in proliferation medium and pulsed with EdU for two hours ([Figure 7C](#fig7){ref-type="fig"}). As expected, the proportion of transduced eGFP-expressing myoblasts incorporating EdU was significantly reduced when either DUX4 was expressed or when *Ret* was knocked down via siRNA transfection. Transfection of *Ret* siRNA into DUX4-expressing cells did not significantly alter the proportion of cells incorporating EdU relative to control siRNA treated cells. Knockdown of *Ret* did not rescue the reduced number of eGFP+/Pax7+ myoblasts in the presence of DUX4 ([Figure 7D](#fig7){ref-type="fig"}). Together, this suggests that *Ret* knockdown is unable to rescue the DUX4-mediated proliferation defect in murine primary myoblasts.

We then tested whether knockdown of *Ret* by siRNA could rescue myoblast differentiation in the presence of DUX4 ([Figure 7E](#fig7){ref-type="fig"}). To assess significant rescue, to compensate for any biological variability and to identify interaction effects, we fitted the data to a binomial model. There was a slight increase in the fusion index of myoblasts expressing control retrovirus and transfected with siRNA against *Ret* relative to control siRNA (p=3.06 × 10^--4^, [Figure 7E, F and G](#fig7){ref-type="fig"}, [Figure 7---source data 1](#SD1-data){ref-type="supplementary-material"}). Myoblasts expressing DUX4 (GFP+) had a dramatically reduced fusion index when transfected with control siRNA (p=2.71 × 10^--65^). In contrast, *Ret* knockdown rescued myoblast fusion in the presence of DUX4, relative to cells expressing DUX4 and transfected with a control siRNA (p=2.15 × 10^--21^). Therefore, *Ret* knockdown significantly improves myogenic differentiation in the presence of DUX4.

Sunitinib, a clinically-approved kinase inhibitor, suppresses Ret signalling to rescue myogenic differentiation {#s2-9}
---------------------------------------------------------------------------------------------------------------

Next, we evaluated small molecule inhibitors of RET for their ability to affect myogenesis in the presence of DUX4. Three RTK inhibitors that block RET phosphorylation were tested: Zactima (Vandetanib/ZD6474) ([@bib13]), TG101209 ([@bib71]) and Sunitinib (Sutent, SU11248) ([@bib42]). Zactima and Sunitinib are both clinically approved as therapeutic agents for treating cancers arising from over-activation of RET signalling ([@bib25]; [@bib99]).

Since Zactima, TG101209 and Sunitinib also inhibit several RTKs other than RET, including *VEGFR, EGF* and *MET* ([@bib73]), we first determined the dose needed to inhibit RET signalling and rescue differentiation in murine myoblasts. We tested different concentrations of each drug on CA RET51-expressing murine C2C12 myoblasts, since we found that CA RET51 inhibits myotube formation in this immortalised myoblast line. Thus, fusion in the presence of CA RET51 would indicate that the drug inhibits this constitutively-active human RET mutant. Statistical models revealed that all inhibitors significantly rescued muscle differentiation in CA RET51-expressing C2C12s ([Figure 8A--C](#fig8){ref-type="fig"}, Sunitinib: p=2 × 10^--16^, TG101209: p=2 × 10^--16^, Zactima: p=4.18 × 10^--14^, [Figure 8---source data 1](#SD2-data){ref-type="supplementary-material"}). This occurred in a dose-dependent manner with Sunitinib, and to an extent, with TG101209. Crucially, this dose-dependent response to Sunitinib and TG101209 occurred without overtly affecting cell number ([Figure 8D--F](#fig8){ref-type="fig"}, [Figure 8---source data 2](#SD3-data){ref-type="supplementary-material"}). Control C2C12 myoblasts were unaffected by Sunitinib and TG101209 at low doses (up to 250 ng/ml), but at higher doses, showed a small increase in fusion index. In contrast, Zactima significantly affected cell number in a non-dose dependent manner and had a strong effect on fusion in control samples ([Figure 8C and F](#fig8){ref-type="fig"} and [Figure 8---source data 2](#SD3-data){ref-type="supplementary-material"}). Sunitinib was selected for further analysis, as it promoted an effective rescue of fusion in the presence of CA RET51, without causing large changes to cell number ([Figure 8G](#fig8){ref-type="fig"}).10.7554/eLife.11405.010Figure 8.Sunitinib blocks the RET-induced phenotype in murine myoblasts.(**A**--**C**) Quantification of the fusion index of C2C12 myoblasts transduced with control (red) or *CA RET51*-encoding retrovirus (blue) and treated with Sunitinib, TG101209 or Zactima at varying doses is shown as a statistical model fitted to the --log of the odds ratio of the fusion index (-log ratio/(1-ratio)) ([Figure 8---source data 1](#SD2-data){ref-type="supplementary-material"}). (**D**--**F**) Quantification of the number of C2C12 myoblasts transduced with control (red) or *CA RET51*-encoding retrovirus (blue) when treated with Sunitinib, TG101209 or Zactima at varying doses ([Figure 8---source data 2](#SD3-data){ref-type="supplementary-material"}). (**G**) C2C12 myoblasts transduced with control or *CA RET51*-encoding retrovirus and induced to differentiate for 60 hr in the presence of either 1 µg/ml Sunitinib or DMSO vehicle control, before co-immunolabelling with antibodies to eGFP (green) to detect transduced cells and MyHC (red), with a DAPI nuclear counterstain (blue). All quantification represents an average of three independent experiments. Scale bar equals 200 µm. (**H**) Representative immunoblot of proteins extracted from un-induced iC2C12-DUX4 myoblasts, or cells induced with 500ng/ml doxycycline (Dox) to express DUX4, 250 ng/ml Sunitinib or both doxycycline and Sunitinib. Probed with antibodies against DUX4, total AKT, phosphorylated (p) AKT, total ERK1/2 and phosphorylated (p) ERK1/2, with Caveolin-1 used as a loading control. All bands shown were visualised on the same membrane. (**I** and **J**) Protein band intensity was quantified with the ChemiDoc MP System and normalised to housekeeping protein Caveolin-1. The ratios of pERK1/2: total ERK1/2 and pAKT: total AKT in the treated groups were compared to the ratios in the control group. Quantification of the ratio between pERK1/2: total ERK1/2 compared to control shows that Sunitinib suppresses DUX4-mediated pERK1/2 signalling. Data is mean ± SEM from 3 independent experiments, where an asterisk denotes a significant difference (p\<0.05) from Control using an unpaired Student's *t*-Test.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.010](10.7554/eLife.11405.010)10.7554/eLife.11405.011Figure 8---source data 1.Maximum likelihood parameters for a logistic model containing an interaction term and a random effect (mouse) to describe the effect of CA RET51 (RET51-MENA) expression and Sunitinib, TG101209 or Zactima on fusion in C2C12 myoblasts.(**a**) Maximum likelihood parameters for a logistic model containing an interaction term and a random effect (mouse) to describe the effect of RET51-MENA expression and Sunitinib, TG101209 or Zactima on fusion in C2C12 myoblasts. (**b**) Maximum likelihood parameters for a logistic model containing an interaction term for RET51-MEN2A and Sunitinib (RET51CA:Sunitinib), Ret51-MEN2A with TG101209 (RET51CA: TG101209) or Ret5-MEN2A with Zactima (RET51CA:Zactima) that reveals the gradient of response of myoblast fusion. Significance of interaction effects relative to the baseline (MIG control retrovirus infected cells with no drug present) is indicated by p values. *y* represents the log of the odds of the fusion index, µ represents the intercept parameter (representing the control treatment: MIG control retrovirus with no drug), *β* are the parameters representing the effects of each treatment, or the interaction as specified, *c* is a parameter representing the effect of concentration of a drug and δ indicates whether the effect is present or absent.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.011](10.7554/eLife.11405.011)10.7554/eLife.11405.012Figure 8---source data 2.Quasi-Poisson model parameters for a fixed-effects factorial model incorporating a parameter to account for the replicate effects (Batch) on the number of cells expressing CA RET51 (RET51-MEN2A) or control when treated with different concentrations of Sunitinib, TG101209 or Zactima.The significance of each effect and combined effects relative to the baseline (control (MIG) infected cells from Batch A with no drug present) is indicated by p values. *y* represents the log of the number of cells, µ represents the intercept parameter (representing the control treatment: MIG control retrovirus with no drug), *β* are the parameters representing the effects of each treatment, or the interaction as specified and δ indicates whether the effect is present or absent.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.012](10.7554/eLife.11405.012)

Sunitinib suppresses DUX4-mediated pERK1/2 signalling {#s2-10}
-----------------------------------------------------

To address the mechanism of Sunitinib in myoblasts, we examined characterised downstream targets of Ret signalling, namely phosphorylated ERK1/2 (pERK1/2) and phosphorylated AKT (pAKT) e.g. ([@bib61]). DUX4 was induced in iC2C12-DUX4 myoblasts using 500 ng/ml doxycycline with or without the addition of 250 ng/ml Sunitinib for 20 hr ([Figure 8H](#fig8){ref-type="fig"}). Western blot analysis showed that Sunitinib significantly reduced pERK1/2 levels in DUX4-expressing myoblasts, without affecting total ERK ([Figure 8H and I](#fig8){ref-type="fig"}). Total AKT and pAKT levels were unaltered by Sunitinib for 20 hr in iC2C12-DUX4 myoblasts expressing DUX4 ([Figure 8H and J](#fig8){ref-type="fig"}).

Sunitinib does not rescue proliferation or apoptosis in DUX4-expressing murine myoblasts {#s2-11}
----------------------------------------------------------------------------------------

We first assessed how 250 ng/ml Sunitinib affected proliferation in DUX4-expressing primary murine satellite cells by measuring EdU incorporation ([Figure 9A](#fig9){ref-type="fig"}). There was no significant difference in proliferation of control cells treated with DMSO vehicle control (43.5 ± 2.0%) or Sunitinib (43.3 ± 0.7%). Proliferation in DUX4-expressing myoblasts was also unaffected by Sunitinib (8.6 ± 2.0%) compared to DUX4-expressing cells treated with DMSO (8.7 ± 1.7%, p\<0.05) ([Figure 9A](#fig9){ref-type="fig"} and [Figure 9---source data 1](#SD4-data){ref-type="supplementary-material"}).10.7554/eLife.11405.013Figure 9.Sunitinib does not prevent apoptosis in DUX4-expressing myoblasts.(**A**--**B**) Quantification of murine satellite cell-derived myoblasts transduced with control or DUX4-encoding retrovirus and treated with either 250 ng/ml Sunitinib (blue) or DMSO vehicle control (red). Cells were cultured at low density and incubated in proliferation medium prior to immunolabelling to detect eGFP and either EdU (**A**) or MyoD (**B**). The ratio represents the proportion of cells with EdU (**A** and [Figure 9---source data 1](#SD4-data){ref-type="supplementary-material"}) or MyoD (**B** and [Figure 9---source data 2](#SD5-data){ref-type="supplementary-material"}) labelling in the presence (True, blue), or absence of Sunitinib (False, red). Bar represents statistical test significance, where an asterisk denotes p\<0.01 or N.S. means non-significant.(**C**) FACS analysis of murine iC2C12-DUX4 myoblasts cultured in control medium (UI) or induced to express DUX4 with 250 ng/ml or 500 ng/ml doxycycline and untreated (0), or exposed to 250 ng/ml or 500 ng/ml Sunitinib for 24 hr. (**D**) Quantification of the mean proportion of apoptotic iC2C12-DUX4 myoblasts based upon the expression of Annexin V and propidium iodide (PI). As a control, an asterisk denotes increased apoptosis by DOX-mediated induction of DUX4 compared to un-induced cells (all without Sunitinib treatment). An average of 3 independent experiments, where statistical difference to myoblasts not exposed to Sunitinib at each concentration of doxycycline was tested using an unpaired two-tailed Student *t*-test, where p\<0.05 represents significance (\*).**DOI:** [http://dx.doi.org/10.7554/eLife.11405.013](10.7554/eLife.11405.013)10.7554/eLife.11405.014Figure 9---Source data 1.Maximum likelihood parameters for a logistic model containing an interaction term, and a random effect term (the mouse) that describes the proportion of myoblasts transduced with DUX4 or control retrovirus and incorporating EdU when exposed to Sunitinib or DMSO.(**a**) Maximum likelihood parameters for a logistic model containing an interaction term, and a random effect term (the mouse) that describes the proportion of myoblasts incorporating EdU transduced with DUX4 or control (MIG) retrovirus when exposed to Sunitinib or DMSO. *y* represents the probability of EdU incorporation. µ represents the intercept parameter (representing the control treatment: MIG control retrovirus with no drug), *β* are the parameters representing the effects of each treatment, or the interaction as specified and δ indicates whether the effect is present or absent. (**b**) Corresponding log of odds ratios computed from the model, for all 4 tested conditions.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.014](10.7554/eLife.11405.014)10.7554/eLife.11405.015Figure 9---Source data 2.Maximum likelihood parameters for a logistic model containing an interaction term, and a random effect term (the mouse) that describes the proportion of cells transduced with DUX4 or control retrovirus and expressing MyoD when exposed to Sunitinib or DMSO.(**a**) Maximum likelihood parameters for a logistic model containing an interaction term, and a random effect term (the mouse) that describes the proportion of cells expressing MyoD transduced with DUX4 or MIG control retrovirus when exposed to Sunitinib or DMSO. *y* represents the probability of MyoD expression. µ represents the intercept parameter (representing the control treatment: MIG control retrovirus with no drug), *β* are the parameters representing the effects of each treatment, or the interaction as specified and δ indicates whether the effect is present or absent. (**b**) Corresponding log of odds ratios computed from the model, for all 4 tested conditions.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.015](10.7554/eLife.11405.015)

DUX4 expression in myoblasts also leads to repression of MyoD ([@bib11]; [@bib84]). Treatment with Sunitinib rescued the number of MyoD-containing myoblasts in the presence of DUX4 when analysed by a statistical model (p=3.8 × 10^−4^), although the relative change was not large ([Figure 9B](#fig9){ref-type="fig"} and [Figure 9---source data 2](#SD5-data){ref-type="supplementary-material"}).

Additionally although expression of Ret in satellite cell-derived myoblasts was not apoptotic ([Figure 7B](#fig7){ref-type="fig"}), it was important to understand whether Sunitinib affects apoptosis in DUX4-expressing cells. iC2C12-DUX4 myoblasts were induced with 250 ng/ml and 500 ng/ml doxycycline for 24 hr, which resulted in apoptosis ([Figure 9C](#fig9){ref-type="fig"}), and exposed to either 250 ng/ml or 500 ng/ml Sunitinib. Live cells were stained with fluorescent-conjugated apoptotic markers Annexin V (AV) and propidium iodide (PI), and analysed by flow cytometry ([Figure 9C](#fig9){ref-type="fig"}). While DUX4 expression increased the proportion of iC2C12-DUX4 myoblasts gated as apoptotic (AV+/PI−, AV−/PI+ and AV+/PI+), treatment with Sunitinib had no significant effect ([Figure 9D](#fig9){ref-type="fig"}).

Sunitinib rescues the myogenic capacity of DUX4-expressing murine myoblasts {#s2-12}
---------------------------------------------------------------------------

We next determined whether Sunitinib could rescue fusion in murine satellite cell-derived myoblasts expressing DUX4. Myoblasts were cultured at high density in the presence of 125--500 ng/ml of Sunitinib and induced to differentiate for 24 hr prior to immunolabelling with MyHC ([Figure 10A and B](#fig10){ref-type="fig"}). Fusion of control myoblasts was unaffected by Sunitinib at all doses (quantified in [Figure 10C](#fig10){ref-type="fig"}). Statistical models showed that the treatment of DUX4-expressing (GFP+) myoblasts with Sunitinib increased fusion index at all doses, relative to cells treated with DMSO vehicle control (p\<2 × 10^−16^, [Figure 10C](#fig10){ref-type="fig"}, [Figure 10---source data 1](#SD6-data){ref-type="supplementary-material"}). This also revealed a saturation of the effect of Sunitinib at concentrations above 250 ng/ml. Sunitinib treatment also increased the proportion of large myotubes that formed in the presence of DUX4, and myotubes containing 25+ nuclei were only observed in Sunitinib-treated samples.10.7554/eLife.11405.016Figure 10.Sunitinib rescues differentiation of DUX4-expressing myoblasts.(**A**) Satellite cell-derived myoblasts induced to differentiate in the presence of varying doses of Sunitinib, and immunolabelled for MyHC (red) and counterstained with DAPI (blue). (**B** and **C**) Immunolabelling of satellite cell-derived myoblasts transduced with retrovirus encoding *DUX4* and *GFP* (green) to detect MyHC (red) following treatment with varying doses of Sunitinib in differentiation medium. (**C**) Fusion index calculated as the ratio of nuclei in eGFP+/MyHC+ multinucleate cells/total nuclei ([Figure 10---source data 1](#SD6-data){ref-type="supplementary-material"}). (**D**) Satellite cell-derived myoblasts transduced with control *GFP* or *DUX4* and *GFP*-encoding retrovirus in the presence of 250 ng/ml Sunitinib or DMSO at high density and induced to differentiate for 24 hr before co-immunolabelling with eGFP (green), MyHC (red) and counterstained with DAPI (blue). (**E**) Fusion index quantified with myoblasts exposed to DMSO (False: red) or 250 ng/ ml Sunitinib (True: blue) ([Figure 10---source data 2](#SD7-data){ref-type="supplementary-material"}). (**F** and **G**) Quantification of satellite cell-derived myoblasts transduced with control *GFP* or retrovirus encoding *DUX4* and *GFP* and treated with either 250 ng/ml Sunitinib (blue) or DMSO (red). Cultured at low density in differentiation medium for 24 or 48 hr (D1, D2) to form unfused myocytes and co-immunolabelled with eGFP to identify transduced cells and either Myogenin (**F** and [Figure 10---source data 3](#SD8-data){ref-type="supplementary-material"}) or MyHC (**G** and [Figure 10---source data 4](#SD9-data){ref-type="supplementary-material"}). All experiments were independently performed 3 times. The statistical significance of differences described in [Figure 10---source data 1](#SD6-data){ref-type="supplementary-material"}--[4](#SD9-data){ref-type="supplementary-material"}. Bar represents statistical test significance, where an asterisk denotes p\<0.01. Scale bar equals 200 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.016](10.7554/eLife.11405.016)10.7554/eLife.11405.017Figure 10---source data 1.Maximum likelihood parameters for a logistic model containing an interaction term between DUX4 and Sunitinib that describes the fusion index of satellite-cells grown at high density with or without DUX4 transduction.(**a**) Maximum likelihood parameters for a logistic model containing an interaction term between DUX4 expression and Sunitinib during fusion of satellite-cells grown at high density and transduced with DUX4-expressing retrovirus or control (MIG). *y* represents the log-of-odds of the fusion index. µ represents the intercept parameter (representing the control treatment: no retrovirus, with no drug present), *β* are the parameters representing the effects of each treatment, or the interaction as specified and δ indicates whether the effect is present or absent. (**b**) Corresponding log of odds ratios computed from the model for all 4 tested conditions.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.017](10.7554/eLife.11405.017)10.7554/eLife.11405.018Figure 10---source data 2.Maximum likelihood parameters for a logistic model containing an interaction term, and a random effect term (the mouse) that describes the fusion index of myoblasts transduced with DUX4 or control retrovirus and grown at high density when exposed to Sunitinib or DMSO.(**a**) Maximum likelihood parameters for a logistic model containing an interaction term, and a random effect term (the mouse) that describes the fusion index of cells infected with DUX4 or MIG control retrovirus and grown at high density when exposed to Sunitinib or DMSO. *y* represents the log-of-odds of the fusion index. µ represents the intercept parameter (representing the control treatment: MIG control retrovirus with no drug), *β* are the parameters representing the effects of each treatment, or the interaction as specified and δ indicates whether the effect is present or absent. (**b**) Corresponding log of odds ratios computed from the model, for all 4 tested conditions.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.018](10.7554/eLife.11405.018)10.7554/eLife.11405.019Figure 10---source data 3.Maximum likelihood parameters for a logistic model containing an interaction term, and a random effect term (the mouse) to describe MyoG expression in satellite cell-derived myoblasts expressing DUX4 or control retrovirus and exposed to Sunitinib or DMSO, when grown at low density.(**a**) Maximum likelihood parameters for a logistic model containing an interaction term, and a random effect term (the mouse) to describe MyoG expression in SCs exposed to Sunitinib or DMSO and expressing DUX4 or control (MIG) retrovirus at 1 or 2 days of culture when grown at low density. *y* represents the probability of MyoG expression. µ represents the intercept parameter (representing the control treatment: MIG control retrovirus with no drug), *β* are the parameters representing the effects of each treatment (e.g. β~1~ at day 1, β~2~ at day 2), or the interaction as specified and δ indicates whether the effect is present or absent. (**b**) Corresponding ratios computed from the model, for all 4 tested conditions.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.019](10.7554/eLife.11405.019)10.7554/eLife.11405.020Figure 10---source data 4.Maximum likelihood parameters for a logistic model containing an interaction term, and a random effect term (the mouse) to describe MyHC expression in satellite cell-derived myoblasts expressing DUX4 or control retrovirus and exposed to Sunitinib or DMSO, when grown at low density.(**a**) Maximum likelihood parameters for a logistic model containing an interaction term, and a random effect term (the mouse) to describe the MyHC expression in SCs exposed to Sunitinib or DMSO and expressing DUX4 or control (MIG) retrovirus at 1 or 2 days of culture when grown at low density. *y* represents the probability of MyHC expression. µ represents the intercept parameter (representing the control treatment: MIG control retrovirus with no drug), *β* are the parameters representing the effects of each treatment (e.g. β~1~ at day 1, β~2~ at day 2), or the interaction as specified and δ indicates whether the effect is present or absent. (**b**) Corresponding ratios computed from the model, for all 4 tested conditions.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.020](10.7554/eLife.11405.020)

To directly determine whether there is an interaction between Sunitinib and DUX4 in murine primary myoblasts that positively affects the fusion index, we next transduced myoblasts with control or DUX4 retrovirus in the presence of DMSO or 250 ng/ml Sunitinib and induced them to differentiate for 24 hr at high density ([Figure 10D](#fig10){ref-type="fig"}). We then used a logistic model to evaluate any interaction ([Figure 10E](#fig10){ref-type="fig"}, [Figure 10---source data 2](#SD7-data){ref-type="supplementary-material"}). This revealed that the effect of Sunitinib on fusion is dependent on the presence of DUX4 (p=2 × 10^--16^) and that there is a significant recovery of fusion in the presence of DUX4 that is due to addition of Sunitinib (p=2.3 × 10^--7^).

Sunitinib enables DUX4-expressing murine myoblasts to differentiate independently of fusion {#s2-13}
-------------------------------------------------------------------------------------------

Using a retroviral expression system to express DUX4 resulted in a transduction rate of approximately 40--50%. However, this approach does not allow determination of whether the increased rate of fusion of DUX4-expressing cells in the presence of Sunitinib was due to Sunitinib rescuing the differentiation defect directly, or by simply enabling DUX4-expressing myoblasts to fuse to control, un-transduced myoblasts. To determine whether DUX4-expressing (GFP+) myoblasts could differentiate independently of fusion, we seeded myoblasts at low density before treating with 250 ng/ml Sunitinib and inducing differentiation for 24 or 48 hr. Samples were then analysed on the basis of individual differentiated myocytes using immunolabelling to detect Myogenin and MyHC protein ([Figure 10F and G](#fig10){ref-type="fig"}).

Sunitinib treatment on control-transduced samples did not change the proportion of myoblasts expressing Myogenin (27.4 ± 1.1%), relative to controls (27.6 ± 0.9%) (p=0.86). In contrast, a significant increase (p=0.028) was noted in the proportion of DUX4 expressing (GFP+) myocytes that were Myogenin+ in the presence of Sunitinib (20.8 ± 1.9%) relative to untreated DUX4-expressing myocytes (11.0 ± 0.6%). The proportion of GFP+ myoblasts expressing MyHC was significantly reduced in the presence of DUX4 (2.4 ± 0.6%) relative to control cells (19.4 ± 2.5%, p=0.028) or to cells exposed only to Sunitinib (21.1 ± 2.1%). In the presence of Sunitinib however, the proportion of MyHC+ cells in DUX4-transduced cultures was significantly increased after 24 hr exposure (7.8 ± 1.3%) (p=0.016).

We then used statistical models to evaluate the importance of the interaction between Sunitinib and DUX4 on Myogenin and MyHC expression in myocytes plated at low density ([Figure 10F and G](#fig10){ref-type="fig"}). Sunitinib had no effect on the number of cells containing Myogenin after 24 or 48 hr in control samples, in contrast to the marked reduction with DUX4 (p\<2 × 10^--16^). The addition of Sunitinib significantly rescued Myogenin expression in DUX4-expressing (GFP+) myoblasts at 24 (p\<1.03 × 10^--5^) and 48 hr (p\<1.38 × 10^--5^, [Figure 10F](#fig10){ref-type="fig"}, [Figure 10---source data 3](#SD8-data){ref-type="supplementary-material"}). As with Myogenin, Sunitinib significantly increased the proportion of DUX4-expressing (GFP+) cells with MyHC at 24 hr (p=4.21 × 10^--5^) and 48 hr (p=7.94 × 10^−3^, [Figure 10G](#fig10){ref-type="fig"}, [Figure 10---source data 4](#SD9-data){ref-type="supplementary-material"}), thus Sunitinib improves myogenic differentiation/fusion.

Sunitinib treatment improves proliferation and differentiation of FSHD myoblasts {#s2-14}
--------------------------------------------------------------------------------

To determine whether Sunitinib improves myogenic differentiation in human FSHD myoblasts, we obtained clonal cell lines derived from a mosaic FSHD1 individual ([@bib49]): a control clone containing a 'healthy' number of D4Z4 repeats (54.6) and a clone containing a pathogenic contraction of *D4Z4* units and expressing DUX4 (54.12), thus apart from the number of DUX4 repeats, both have the same genetic background. Although both clones proliferate and undergo differentiation in culture ([@bib49]), we found that the 54.12 pathogenic line proliferated at a slower rate, had an eccentric cell shape and differentiated into smaller myotubes than the healthy 54.6 control myoblasts, as revealed by a lower fusion index ([Figure 11](#fig11){ref-type="fig"}). This phenotype is similar to that reported for primary myoblasts from FSHD patients ([@bib7]).10.7554/eLife.11405.021Figure 11.Sunitinib improves the pathogenic phenotype of FSHD myoblasts.(**A**) Immunolabelling of mosaic FSHD patient-derived myoblast cell lines 54.6 (control) and 54.12 (FSHD) exposed to DMSO vehicle control or 500 ng/ml Sunitinib. EdU incorporation (red) was revealed using the Click-iT assay and myoblasts immunolabelled for β-TUBULIN (green) with a DAPI nuclear counterstain (blue). (**B**) Immunolabelling of MYHC (red) in myoblasts grown at high density in differentiation medium with either DMSO vehicle control or 500 ng/ml Sunitinib. (**C**--**E**) Quantification of cell shape (eccentricity) assessed using β-TUBULIN immunolabelling (**C** and [Figure 11---source data 1](#SD10-data){ref-type="supplementary-material"}), EdU incorporation (**D** and [Figure 11---source data 2](#SD11-data){ref-type="supplementary-material"}) and fusion index (**E** and [Figure 11---source data 3](#SD12-data){ref-type="supplementary-material"}) plotted relative to varying Sunitinib concentrations in 54.6 control (red) and 54.12 FSHD (blue) myoblasts. Statistical analysis described in [Figure 11---source data 1](#SD10-data){ref-type="supplementary-material"}--[3](#SD12-data){ref-type="supplementary-material"}. All experiments were independently performed 3 times. Bar represents statistical test significance at each concentration of Sunitinib, where an asterisk denotes p\<0.01, while N.S. means non-significant. Scale bars equal 50 µm (**A**) 200 µm (**B**).**DOI:** [http://dx.doi.org/10.7554/eLife.11405.021](10.7554/eLife.11405.021)10.7554/eLife.11405.022Figure 11---source data 1.A linear model that describes the relationship between the shape (eccentricity) of control 54.6 and FSHD 54.12 human myoblasts relative to different doses of Sunitinib.The model is a linear model that describes the relationship between the shape (eccentricity) of 54.6 (control) and 54.12 (FSHD) cells relative to different doses of Sunitinib. P values are approximate and are based on the t-value and represent the probability that there is a difference in cell shape at a specific concentration of Sunitnib. *y* represents cell eccentricity, µ represents the intercept parameter (representing the control treatment: 54.6 cells with no drug), *β* are the parameters representing the effects of each treatment, or the interaction as specified and δ indicates whether the effect is present or absent.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.022](10.7554/eLife.11405.022)10.7554/eLife.11405.023Figure 11---source data 2.A binomial model that tests the relationship between the proliferation of control 54.6 and FSHD 54.12 human myoblasts with different doses of Sunitinib.(**a**) Maximum likelihood parameters for a logistic model containing an interaction term between the cell line and sunitinib and incorporating a random effect term (the experiment). The model is a binomial model that tests the relationship between the proliferation of 54.6 (control) and 54.12 (FSHD) cells relative to different doses of Sunitinib. P values represent the probability of a difference in proliferation between the control cells with varying doses of Sunitinib and between control and FSHD cells at different doses of Sunitinib. *y* represents the proliferation index. µ represents the intercept parameter (representing the control treatment: 54.6 cells with no drug), *β* are the parameters representing the effects of each treatment, or the interaction as specified and δ indicates whether the effect is present or absent. (**b**) Corresponding log of odds ratios computed from the model, for all 4 tested conditions.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.023](10.7554/eLife.11405.023)10.7554/eLife.11405.024Figure 11---source data 3.A binomial model that tests the relationship between the fusion of control 54.6 and FSHD 54.12 human myoblasts relative to different doses of Sunitinib.(**a**) Maximum likelihood parameters for a logistic model containing an interaction term between the cell line and Sunitinib and incorporating a random effect term (the experiment). The model is a binomial model that tests the relationship between the fusion of 54.6 (control) and 54.12 (FSHD) cells relative to different doses of Sunitinib. Estimate represents the relative change in fusion between conditions. p values represent the probability of a difference in fusion between the control cells with varying doses of Sunitinib and between control and FSHD cells at different doses of Sunitinib. *y* represents the log-of-odds of the fusion index. µ represents the intercept parameter (representing the control treatment: 54.6 cells with no drug), *β* are the parameters representing the effects of each treatment, or the interaction as specified and δ indicates whether the effect is present or absent. (**b**) Corresponding log of odds ratios computed from the model, for all 4 tested conditions.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.024](10.7554/eLife.11405.024)

To determine if Sunitinib was able to rescue pathogenic phenotypes in the human FSHD cell line, we treated both cell lines with varying concentrations of Sunitinib in either proliferation or differentiation medium. There was no change in cell shape (eccentricity) of 54.6 control myoblasts in the presence of Sunitinib at any dose ([Figure 11A and C](#fig11){ref-type="fig"}). While 54.12 FSHD myoblasts treated with vehicle control or the lower doses of Sunitinib (125 or 250 ng/ml) retained a significantly more elongated cell shape relative to control 54.6 myoblasts (p\<0.01), myoblasts treated with higher doses of Sunitinib no longer exhibited an abnormal cell shape compared to 54.6 controls ([Figure 11C](#fig11){ref-type="fig"}, [Figure 11---source data 1](#SD10-data){ref-type="supplementary-material"}).

Importantly, the reduced proliferation rate of FSHD 54.12 myoblasts compared to 54.6 (p=2.55 × 10^--5^) was rescued upon exposure to 250 ng/ml, 500 ng/ml or 750 ng/ml of Sunitinib, concentrations which did not affect control 54.6 myoblasts ([Figure 11A and D](#fig11){ref-type="fig"}, [Figure 11---source data 2](#SD11-data){ref-type="supplementary-material"}).

Fusion of control 54.6 myoblasts was increased by Sunitinib at small, but significant, levels in a non-linear manner. In contrast, Sunitinib had a strong and highly significant effect on the fusion index of 54.12 cells at all concentrations tested (p\<2 × 10^--16^). The fusion index increased in a dose-dependent manner in the presence of 125 or 250 ng/ml of Sunitinib. 250 ng/ml Sunitinib had the most potent effect on fusion of 54.12 myoblasts, achieving a level that was comparable to that of 54.6 myoblasts ([Figure 11B and E](#fig11){ref-type="fig"}). At doses of 500 or 750 ng/ml Sunitinib, a fusion of 54.12 myoblasts was not enhanced to similar levels as observed at 250 ng/ml, suggestive of inhibitory effects at these higher doses ([Figure 11B and E](#fig11){ref-type="fig"}, [Figure 11---source data 3](#SD12-data){ref-type="supplementary-material"}).

Thus, in myoblasts lacking the FSHD1-specific D4Z4 contraction, Sunitinib does not have a large effect on human myoblast morphology, proliferation or ability to form multinucleated myotubes. In contrast, myoblasts containing the D4Z4 contraction are sensitive to Sunitinib, which alters cell morphology to resemble control myoblasts. Importantly, these FSHD human myoblasts have an increased proliferation rate and greater myogenic differentiation capacity when treated with Sunitinib.

Sunitinib improves the regenerative capacity of FSHD myoblasts in vivo {#s2-15}
----------------------------------------------------------------------

We then tested whether Sunitinib could improve the regenerative capacity of human FSHD 54.12 myoblasts in vivo by grafting into regenerating muscles of immunodeficient, NOD/scid/γ-chain knockout mice ([Figure 12](#fig12){ref-type="fig"}). Mice were pre-treated with an intraperitoneal injection of 20 mg/kg Sunitinib malate or PBS control for 24 hr prior to cryoinjury of the tibialis anterior (TA) muscle to induce regeneration. TA muscles were then grafted intramuscularly with 1 × 10^6^ 54.12 FSHD myoblasts, which had been cultured in control medium or pre-treated with 250 ng/ml Sunitinib for 24 hr. Mice were given 20 mg/kg/day Sunitinib or PBS for 3 weeks.10.7554/eLife.11405.025Figure 12.Sunitinib improves engraftment and differentiation of human FSHD myoblasts in murine skeletal muscle.(**A**) Representative 8 μm thick cryosections from the tibialis anterior (TA) muscle of immunodeficient mice transplanted with 1 × 10^6^ human 54.12 FSHD myoblasts per muscle, and dosed with 20 mg/kg/day Sunitinib or PBS (control) for 3 weeks. Immunofluorescence for human-specific LAMIN A/C (green) and SPECTRIN (green) reveal the location and fate of transplanted cells, murine Laminin (red) delimits all myofibres and Hoechst (blue) reveals total nuclei. (**B**) Quantification of the total number of LAMIN A/C cells from each section per TA, subdivided into cells located in the interstitum (grey hatched) and nuclei (myonuclei) within myofibres (black) (also see [Figure 12---source data 1](#SD13-data){ref-type="supplementary-material"}). (**C**) Quantification of the mean number of human SPECTRIN positive myofibres per TA section (also see [Figure 12---source data 2](#SD14-data){ref-type="supplementary-material"}). (**D**) Quantification of the total number of human SPECTRIN positive myofibres containing at least one human LAMIN A/C positive cell. (**E**) The mean number of SPECTRIN-positive myofibres per TA section along the length of the muscle. Data is mean ± SEM from 4 control and 4 Sunitinib-treated mice, with statistical significance (p\<0.05) tested against control mice using an unpaired Student's *t*-test and indicated with an asterisk. Further statistical analysis is described in [Figure 12---source data 1](#SD13-data){ref-type="supplementary-material"} and [2](#SD14-data){ref-type="supplementary-material"}. Scale bar represents 100 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.025](10.7554/eLife.11405.025)10.7554/eLife.11405.026Figure 12---source data 1.A binomial model evaluating whether the proportion of LAMIN A/C+ nuclei derived from grafted FSHD 54.12 human myoblasts in a muscle fibre is significantly affected by exposure to Sunitinib.(**a**) Maximum likelihood parameters for a logistic model containing a random effect term (the mouse) describing the probability of a human LAMIN A/C+ nuclei being present in a murine muscle fibre. (**b**) Corresponding ratios computed from the model for 2 conditions with the ratio representing the probability of a LAMIN A/C+ nuclei occurring in a muscle fibre. In all condition but the control (Intercept), the error contribution of the baseline (Intercept) has been omitted when computing the confidence intervals (C.I.). *y* represents the log-of-odds of the LAMIN A/C+ nuclei occurring in a muscle fibre relative to all LAMIN A/C+ nuclei. µ represents the intercept parameter (representing the control treatment: PBS), *β* are the parameters representing the effects of each treatment and δ indicates whether the effect is present or absent.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.026](10.7554/eLife.11405.026)10.7554/eLife.11405.027Figure 12---source data 2.A binomial model evaluating whether the proportion of muscle fibres containing SPECTRIN and LAMIN A/C derived from grafted FSHD 54.12 human myoblasts is significantly affected by exposure to Sunitinib.(**a**) Maximum likelihood parameters for a logistic model containing a random effect term (the mouse) describing the probability of a SPECTRIN+ murine muscle fibre containing LAMIN A/C+ nuclei . (**b**) Corresponding ratios computed from the model for 2 conditions with the ratio representing the probability of a SPECTRIN+ murine muscle fibre containing LAMIN A/C+ nuclei. In all condition but the control (Intercept), the error contribution of the baseline (Intercept) has been omitted when computing the confidence intervals (C.I.). *y* represents the log-of-odds of a SPECTRIN+ muscle fibre containing LAMIN A/C+ nuclei. µ represents the intercept parameter (representing the control treatment: PBS), *β* are the parameters representing the effects of each treatment and δ indicates whether the effect is present or absent.**DOI:** [http://dx.doi.org/10.7554/eLife.11405.027](10.7554/eLife.11405.027)

Analysis was performed blinded. After 3 weeks, the TA muscles were removed and serial cryosections cut along the length of the muscle. Cryosections were immunostained with human-specific antibodies against LAMIN A/C to quantify donor cell engraftment and SPECTRIN to measure myogenic differentiation of donor myoblasts ([Figure 12A](#fig12){ref-type="fig"}). There was a significant increase in both the total number of LAMIN A/C positive cells (total from all cryosections along the length of the muscle) ([Figure 12B](#fig12){ref-type="fig"}, [Figure 12---source data 1](#SD13-data){ref-type="supplementary-material"}) and the number of LAMIN A/C positive cells located within myofibres (myonuclei), in mice treated with Sunitinib compared to controls ([Figure 12B](#fig12){ref-type="fig"}). The mean number of SPECTRIN positive myofibres per section ([Figure 12C](#fig12){ref-type="fig"}, [Figure 12---source data 2](#SD14-data){ref-type="supplementary-material"}) and the total number of LAMIN A/C positive cells located within SPECTRIN-positive myofibres ([Figure 12D](#fig12){ref-type="fig"}) were also increased significantly in mice treated with Sunitinib compared to controls. Finally, increased engraftment in Sunitinib-treated samples was also seen along the length of the muscle ([Figure 12E](#fig12){ref-type="fig"}). Taken together, this shows that Sunitinib treatment improves the regenerative capacity of human FSHD myoblasts by increasing their engraftment and myogenic differentiation.

Discussion {#s3}
==========

We report that Ret is a novel mediator of muscle stem cell function, is regulated by DUX4 and contributes to the pathogenic phenotype of FSHD. We focused on Ret signalling as a potential mediator of DUX4-induced muscle pathology for several reasons. FSHD is characterised by the often asymmetric wasting of facial, shoulder and upper arm muscles ([@bib89]), and can be associated with several non-muscle tissue pathologies including sensorineural hearing loss and retinal vasculopathies ([@bib96]). Development of the auditory system, retinal patterning and facial muscles have been shown to depend on Ret signalling in a number of species. *Ret* is expressed in the second pharyngeal arch, from which some facial muscles arise, both in mouse and zebrafish ([@bib44]; [@bib70]). Additionally, Ret, GFRα1 and GFRα2 are expressed in the retina and the sensory epithelium of the cochlea, both of which can be affected in FSHD ([@bib32]; [@bib115]; [@bib110]). Phenotypic analysis of *Ret, GFRa* ([@bib26]; [@bib91]; [@bib78]; [@bib36]; [@bib56]) and *GFL* ([@bib36]; [@bib62]; [@bib35]; [@bib90])-mutant mice have not reported a skeletal muscle phenotype, although this may have been overlooked due to the severe phenotype and perinatal lethality of some mutant lines. However, *Ret* is expressed in the indirect flight muscles of *Drosophila*, and overexpression of constitutively active *Ret* (RET^MEN2B^) in muscle via a MEF2-GAL4 driver causes increased muscle fibre size, irregular myofibrils and abnormal actin deposits ([@bib43]). Interestingly, irregular myotube morphology is often reported in FSHD patient-derived cultures ([@bib7]; [@bib87]). As we found that Ret was activated by DUX4 in murine satellite cells, it becomes a potential candidate for contributing to DUX4-induced myopathy.

There has been no description of Ret function during myogenesis in mammals, despite the descriptions of Ret pathway genes expressed in specific muscle cell populations, including facial muscle precursors ([@bib32]; [@bib67]; [@bib44]). We found that *Ret* and three of its co-receptors: *Gfrα1, Gfrα2* and *Gfrα4* are dynamically expressed in mammalian limb satellite cells. Intriguingly, *Ret* expression was higher during proliferation, whereas *Gfrα1, Gfrα2* and *Gfrα4* expression increased upon differentiation. This reciprocal expression pattern between *Ret* and its co-receptors also occurs in other cell types ([@bib54]) and so may regulate Ret signalling by feedback loops. Additionally, the ligands GDNF and PSPN, required to activate Gfrα1 and Gfrα4 (and to a lesser extent Gfrα2), are expressed by muscle fibres ([@bib32]; [@bib107]; [@bib56]), suggesting that myofibres may signal to satellite cells via Ret signalling. We also found that *RET* is expressed at low levels in primary human myoblasts, revealing a conserved expression in vertebrate muscle. Constitutive-expression and knockdown studies revealed that Ret signalling is required to maintain a proliferating myoblast population and prevent premature cell cycle exit and myogenic differentiation. Specifically, constitutively active RET increased satellite cell proliferation but did not affect terminal differentiation. Consistent with this, siRNA-mediated knockdown of Ret reduced *Pax7* expression, concomitant with reduced satellite cell proliferation, whilst increasing differentiation. Knockdown of Gfrα1, Gfrα2 or Gfrα4 causes similar, if less severe, defects suggesting that Ret is interacting with its Gfrα co-receptors to control the switch from proliferation to differentiation in myoblasts.

Having shown that Ret is involved in the control of myogenesis, we aimed to understand its role in mediating DUX4 pathology. DUX4 is pathogenic in both myoblasts and differentiated muscle ([@bib95]; [@bib11], [@bib10]; [@bib48]; [@bib97]; [@bib18]). Recent microarray and ChIP-seq datasets reveal that DUX4 causes wide-ranging transcriptional disruption in myogenic cells ([@bib30]; [@bib6]; [@bib75]; [@bib46]) , with its potent transcriptional activation through its C-terminal domain ([@bib30]; [@bib16]; [@bib41]). However, identifying which disrupted pathways directly contribute to DUX4-specific pathology is crucial when considering future drug design to treat FSHD.

Ret is genetically downstream of DUX4 in myoblasts, but does not appear to be a direct transcriptional target. Transgenic analysis has shown that in mouse, 1.9 kb 5' of the Transcriptional Start Site (TSS) of *Ret* is sufficient to drive tissue specific expression ([@bib115]). However, analysing two published ChIP-Seq datasets of DUX4 overexpression in human myoblasts ([@bib30]; [@bib15]), we failed to identify significant peaks within 15 kb 5' of the *Ret* TSS. In addition, sequence analysis also failed to find a DUX4 consensus binding site (TAATCTAATCA -- \[[@bib114]\]) within this same 15 kb region. It is of note however, that the C-terminus of DUX4 can recruit acetyltransferases (p300/CBP) to histones to induce acetylation, hence promoting transcription at sites distant to DUX4 DNA binding ([@bib15]), so DUX4 could still directly controlling *Ret* in an epigenetic manner. However, also arguing against Ret being a direct transcriptional target of DUX4 is our observation that *Ret* expression is not only enhanced by DUX4 and the constitutively active tMALDUX4-VP16, but also by our DUX4 dominant-negative tMALDUX4-ERD construct in the microarray analysis. The tMALDUX4-ERD construct contains the two DNA binding homeodomains of DUX4, so should select the same cohort of transcriptional targets as DUX4. However, if DUX4 binds directly to the *Ret* promoter, tMALDUX4-ERD should suppress transcription and so reduce Ret expression, but this is the opposite to what we observe. Together, these observations indicate that DUX4 affects *Ret* expression indirectly, via binding to genes that, in turn, control *Ret* expression.

Blocking *Ret* expression or signalling increases the probability of DUX4-expressing myoblasts to differentiate into multinucleate myotubes. Despite this, some aspects of DUX4-mediated pathologies were not rescued by Ret inhibition. For example, inhibition of Ret using Sunitinib did not alter DUX4-induced apoptosis. DUX4 transcriptionally dysregulates a large number of pathways, so it is unlikely that one pathway only is responsible for all pathological characteristics ([@bib6]). For example, we have recently shown that β-catenin signalling is important for DUX4-mediated transcriptional dysregulation in skeletal muscle ([@bib6]).

To investigate the relative importance of Ret in mediating DUX4 action, we adopted a pharmacological approach that allowed us to modify Ret signalling in a dose-dependent manner. As the readout, we used the suppression of differentiation caused by constitutive CA RET51 (RET51-MENA) expression in murine C2C12 myoblasts and asked at which doses we could inhibit Ret to rescue differentiation, without causing deleterious side-effects. Comparison of Ret inhibitors Zactima (Vandetanib/ZD6474) ([@bib13]), TG101209 ([@bib71]) and Sunitinib (Sutent, SU11248) ([@bib42]) revealed that Suntinib showed the most robust rescue of CA RET51-mediated inhibition of myogenesis. We further tested the ability of Sunitinib to rescue DUX4-mediated phenotypes in murine satellite cells and showed that we could again rescue differentiation, but not proliferation: consistent with the effects of siRNA-mediated knockdown of *Ret*. Zactima, TG101209 and Sunitinib also inhibit other receptor tyrosine kinases, including *VEGFR, EGF* and *MET* ([@bib73]). Of note, *Vegfr2* is also a DUX4 target identified in our microarray screen ([@bib6]), highlighting another potential mediator of DUX4 pathology in myoblasts. Since many of these receptors activate the same intracellular pathways as Ret, it will be important to understand their relative roles and redundancies, when activated in the context of FSHD.

Since DUX4 up-regulates *Ret,* and Sunitinib can clearly rescue the differentiation block caused by CA-RET51 in C2C12 myoblasts, we investigated intracellular signalling events. ERK and AKT are two key intracellular mediators of Ret signalling e.g. ([@bib61]). ERK1/2 phosphorylation was inhibited by Sunitinib in DUX4-expressing iC2C12-DUX4 myoblasts, but not in control myoblasts not expressing DUX4, suggesting a potential mechanism by which DUX4-mediated Ret signalling could inhibit differentiation. In contrast, AKT phosphorylation was unaltered by inducing DUX4. Although Ret can operate through ERK1/2 signalling, it is possible that Sunitinib could also be acting on ERK1/2 phosphorylation activated by other pathways perturbed by, or in response to, DUX4.

To assess whether Sunitinib could be used to ameliorate FSHD pathologies in man, we used human myoblast lines isolated from a mosaic FSHD1 patient ([@bib49]). We assessed whether Sunitinib could rescue cell morphology, proliferation and the differentiation capacity of human myoblasts displaying FSHD pathologies. Using statistical models we showed that Sunitinib could induce the FSHD myoblasts to adopt the phenotype of isogenic myoblasts lacking the D4Z4 contraction. Transplantation assays of FSHD myoblasts into cryodamaged immunodeficient mice showed increased engraftment of FSHD myoblasts occurred in response to daily systemic Sunitinib treatment. Therefore, this pre-clinical model for evaluating modifiers of FSHD pathology identifies Sunitinib as a potential therapeutic agent for FSHD.

In conclusion, we have shown that Ret is a novel regulator of satellite cell function in mammalian muscle, and contributes to the FSHD phenotype. Specifically, blocking DUX4-mediated Ret signalling increases myogenic differentiation, giving further insight into the molecular pathology of DUX4 and highlighting Ret signalling as potential drug target. Crucially, the clinically-approved RET inhibitor Sunitinib ([@bib99]) rescues cell morphology, proliferation and myogenic differentiation in human FSHD myoblasts both in vitro and in vivo. Given that FSHD is currently incurable, our findings highlight RTK inhibitors as a potential novel therapeutic strategy to treat muscle wasting in FSHD.

Materials and methods {#s4}
=====================

Animals {#s4-1}
-------

Experimental procedures were performed in accordance with British law under the provisions of the Animals (Scientific Procedures) Act 1986, as approved by the King's College London and University College London Ethical Review Process committees. C57BL/10 male mice aged between 8 and 10 weeks were used for myofibre and satellite cell-derived myoblast preparations. Immunodeficient NOD/scid/γ-chain mice were used for grafting experiments, performed under UK Home Office Project Licence 70/8566. All surgery was performed under isoflurane anesthesia, and every effort made to minimize pain and suffering, including use of analgesics.

Cell culture and primary satellite cell preparation {#s4-2}
---------------------------------------------------

Single myofibres were isolated from the extensor digitorum longus (EDL) as previously described ([@bib64]). Briefly, dissected EDLs were digested in DMEM (+Glutamax) (Thermo Fisher Scientific, Waltham, MA) containing 0.2% collagenase (Sigma-Aldrich, Dorset, UK) for 2 hr in a 37°C 5% CO~2~ incubator before manual disruption with a heat-polished glass pipette in 5% bovine serum albumin (BSA) (Sigma Aldrich) coated dishes. Individual washed myofibres with associated quiescent satellite cells were subsequently fixed in 4% paraformaldehyde/PBS (PFA) or cultured in non-adherent or adherent conditions. Non-adherent cultures were grown in DMEM-Glutamax (Thermo Fisher Scientific) supplemented with 10% horse serum (HS) (Thermo Fisher Scientific), 0.5% chicken embryo extract (CEE) and 1% Penicillin-Streptomycin (Sigma Aldrich) for up to 72 hr. For adherent cultures of proliferating satellite cells, myofibres were plated on 1 mg/ml Matrigel (Collaborative Research Inc., Bedford, MA) coated dishes in DMEM (Glutamax) supplemented with 20% foetal calf serum (FBS)-Gold (Thermo Fisher Scientific), 10% HS, 1% CEE, 10 ng/ml basic FGF (Peprotech, Rocky hill, NJ) and 1% Penicillin-Streptomycin for 72 hr. Subsequently, myofibres were removed by pipette agitation and satellite cells re-plated after trypsinisation in 0.25% Trypsin-EDTA.

Primary human myoblasts were obtained from biopsies of the vastus lateralis of consenting individuals (approved by the UK National Health Service Ethics Committee (London Research Ethics Committee; reference 10/H0718/10 and in accordance with the Human Tissue Act and Declaration of Helsinki). Biopsies were digested in basal medium (PromoCell containing collagenase B and dispase II) and single cells isolated via 100 μM cell strainer as previously described ([@bib1]). Adherent cells were cultured for 7 days in skeletal muscle cell growth medium (PromoCell, Heidelberg, Germany) and the NCAM/CD56+ myogenic population collected via magnetic activated cell sorting (MACS).

The immortalised human myoblast lines 54.6 (un-contracted *D4Z4*, no DUX4 expression) and 54.12 (contracted *D4Z4*, DUX4 expression) from a mosaic patient were a kind gift from V. Mouly and Silvere van der Maarel ([@bib49]) and were verified by assessing *DUX4* expression and tested for mycoplasma. Both lines were maintained in skeletal muscle cell growth medium (PromoCell, C-23160) and differentiated in skeletal muscle cell differentiation medium (PromoCell supplemented with 50 μg/ml Gentacmycin).

C2C12 myoblasts ([@bib105]), iC2C12-DUX4 and iC2C12-DUX4c myoblasts ([@bib11]) and HEK 293T cells were maintained in DMEM supplemented with 10% FBS, 1% L-Glutamine (Sigma Aldrich) and 1% Penicillin-Streptomycin. For differentiation, both satellite cell-derived myoblasts and C2C12 myoblasts were cultured in mitogen-poor medium, containing DMEM, 2% HS, 1% Penicillin-Streptomycin and 1% L-Glutamine. iC2C12-DUX4 and iC2C12-DUX4c myoblasts were tested for DUX4 and DUX4c induction respectively.

Retroviral expression constructs {#s4-3}
--------------------------------

Plasmids were obtained encoding human *RET9* and *RET51* and constitutively active (CA) forms containing the Cys634Lys mutation that occurs in multiple endocrine neoplasia type 2A (MEN2A) patients ([@bib20]). Coding sequences were sub-cloned into a modified *pMSCV-puro* vector ([Takara Bio Europe](http://www.clontech.com/), Saint-Germain-en-Laye, France), in which the puromycin resistance gene was replaced with an internal ribosomal entry site (IRES) and enhanced green fluorescent protein (eGFP), allowing transduced cells to be identified due to the presence of eGFP ([@bib112]). The DUX4 and DUX4c constructs have previously been published ([@bib6]). All constructs were sequenced to ensure fidelity.

Retroviruses were produced using HEK 293T packaging cells, by co-transfecting the expression vectors in the presence of an ectopic helper plasmid. Replication incompetent viral particles were harvested from the culture medium and expression confirmed by western blot and immunofluorescence.

Retroviral transduction {#s4-4}
-----------------------

C2C12 myoblasts and satellite cell-derived myoblasts were plated at 70% confluency and transduced with control, *RET, RET* mutants, *DUX4c* or *DUX4*-encoding retroviruses in the presence of 4 μg/ml Polybrene for 6 hr at 37°C, 5% CO~2~ in proliferation medium, before the medium was replaced.

siRNA-mediated gene knockdown {#s4-5}
-----------------------------

Satellite cells were transfected with 20 nM of control or *Ret* Silencer Select siRNA (Thermo Fisher Scientific) in the presence of Lipofectamine RNAiMAX (Thermo Fisher Scientific) for 6 hr at 37°C, 5% CO~2~ in proliferation medium. The siRNA sequence 5'-GCUUGUACAUCGGGACUUATT-3' (ID: s72895) was used to knockdown murine *Ret* expression, and control siRNA was supplied by Thermo Fisher Scientific. Gene knockdown was confirmed 48 hr after transfection.

Ret signalling inhibition using clinically approved drugs {#s4-6}
---------------------------------------------------------

Three small molecule tyrosine kinase inhibitors were analysed for their ability to inhibit RET signalling. All drugs are ATP-competitive inhibitors of tyrosine kinases, and were obtained from Selleckchem.com: Sunitinib (Sutent, SU11248) ([@bib42]), TG101209 ([@bib71]) and Zactima ([@bib13]). The chemical structures of each compound can be found in ([@bib71]; [@bib42]; [@bib98]).

Quantitative RT-PCR {#s4-7}
-------------------

Cells were cultured in 6-well plates for at least 48 hr under experimental conditions and total RNA extracted using RNeasy Kit (QIAGEN Ltd, Manchester, UK ). Between 500 ng -- 1 μg of RNA was used to prepare cDNA using the QuantiTect Reverse Transcription Kit with genomic DNA wipeout (QIAGEN). RT-qPCR was performed on an Mx3005PQPCR system (Agilent Technologies LDA UK Ltd, Stockport, UK) with MESA Blue qPCR MasterMix Plus and ROX reference dye (Eurogentec Ltd, Southampton, UK). Primers used were as follows:

Total *Ret* (F: 5'-AAGCAGGAGCCAGACAAGAG-3' and R: 5'-ACACCTTCGGACTCACTGCT-3'),

*Ret9* (F: 5'-GATCCAGAGGCCAGACAAC -3' and R: 5'- GTAGAATCTAGTAAATGCA-3'),

*Ret51* (F: 5'-GATCCAGAGGCCAGACAAC-3' and R: 5'-AGGACTCTCTCCAGGCCAG-3'),

*GFRα1* (F: 5'-GCACAGCTACGGGATGCTC-3' and R: 5'-CTCTGGCTGGCAGTTGGT-3'),

*GFRα2* (F: 5'-ACCGTGTGCCCAGCGAGTATA-3' and R: 5'-CGACAGTTGGCGTGGAAGT-3'), *GFRα3 (F: 5'- GGAAAATGAATCTTAGCAAGTTGAA-3'* and R: 5'- TTGTCGTGAAGAGTACACAGCATAG-3'),

*GFRα4* (F: 5'-ACCCCTGCTTGGATGGTGCC-3' and R: 5'-CAGCCAGGACACCTTGGGCG-3'),

*Gapdh* (F: 5'-GTGAAGGTCGGTGTGAACG-3' and R: 5'-ATTTGATGTTAGTGGGGTCTCG-3')

*Tbp* (F: 5'-ATCCCAAGCGATTTGCTG-3' and R: 5'-CCTGTGCACACCATTTTTCC-3')

Primers for murine *Pax7, MyoD* and *Myf5* have previously been published ([@bib17]). Human primers were as follows:

*RPLPO* (F: 5'- TCTACAACCCTGAAGTGCTTGAT-3' and R: 5'- CAATCTGCAGACAGACACTGG-3')

*Cyclin D1* (F: 5'-GCCGAGAAGCTGTGCATC -3' and R: 5'-CCACTTGAGCTTGTTCACCA-3'),

*MYOD* (F: 5'- GCTCCGACGGCATGATGG -3' and R: 5'- GACACCGCCGCACTCTTCCC -3'), *MYOG* (F: 5'- CCAGGGGTGCCCAGCGAATG -3' and R: 5'- AGCCGTGAGCAGATGATCC -3'), *MyHC* (F: 5'- AGCAGGAGGAGTACAAGAAG -3' and R: 5'- CTTTGACCACCTTGGGCTTC -3') and *RET* (F: 5'-GCTCCACTTCAACGTGTC-3' and R: 5'-GCAGCTTGTACTGGACGTT-3').

Murine samples were normalised to the housekeeping genes *Gapdh* and/or *Tbp* (as designated) and human samples normalised to *RPLPO*.

Immunolabelling {#s4-8}
---------------

Floating myofibres or plated satellite cells were fixed in 4% paraformaldehyde/PBS, permeabilised with 0.5% Triton/PBS (Sigma Aldrich) and blocked in PBS containing 5% swine serum + 5% goat serum (DakoCytomation, Glostrup, Denmark) for 1 hr (except for samples using goat RET51 antibody, which were blocked in 10% swine serum). Samples were incubated in primary antibody overnight at 4°C, washed 3 times in 0.025% Tween/PBS and visualised by incubating with AlexaFluor conjugated secondary antibodies (Thermo Fisher Scientific) at 1/500 dilution for 1 hr at room temperature. Nuclei were visualised by mounting in aqueous mountant containing DAPI (Vectashield), for further detail see ([@bib64]). Primary antibodies used were: goat anti-RET (C-20, Santa Cruz Biotechnology, Dallas TX, 1/150), rabbit anti-RET51 (C-19, Santa Cruz Biotechnology, 1/150) and rabbit anti-pRET (Tyr1062-R, Santa Cruz Biotechnology, 1/150), mouse anti-Pax7 (Developmental Studies Hybridoma Bank, Iowa City, IA, 1/10), mouse anti-Myogenin (F5D, Developmental Studies Hybridoma Bank, 1/10) and mouse anti-MyHC (MF-20, Developmental Studies Hybridoma Bank, 1/300), rabbit anti-eGFP (A11122, Thermo Fisher Scientific, 1/500), chicken anti-eGFP (ab13970, Abcam, Cambridge, UK, 1/1000), rabbit anti-phospho-Histone H1 (06--597 Thermo Fisher Scientific, 1/300), rabbit anti-phospho-Histone H3 (06--570, Thermo Fisher Scientific, 1/100), rabbit anti-Desmin (D93F5, Cell Signalling Technology, Danvers, MA, 1/250), rabbit anti-Ki67 (SP6, A.Menarini Diagnostics Ltd, Winnersh, UK, 1/200) and mouse anti-tubulin (E7-C, Developmental Studies Hybridoma Bank, 1/1000).

EdU analysis was performed with the Click-iT EdU Alexa Fluor Imaging Kit, by incubating cells for 2 hr with 10 μM of 5-Ethynyl-2\'-deoxyuridine (EdU) before fixation and processing as per manufacturer's instructions (Thermo Fisher Scientific).

Immunoblot analysis {#s4-9}
-------------------

HEK 293T cells were transfected with RET expression vectors for 24 hr and total protein extracted in the presence of a complete protease inhibitor cocktail (PIC, Roche Diagnostics Ltd, Burgess Hill, UK). Samples were quantified using the DC Protein Assay (Biorad Laboratories, Hercules, CA, 500--0116) and equal quantifies run on pre-cast 4--20% electrophoresis gels (Thermo Fisher Scientific) with 0.35 μl dithiothreitol and bromophenol blue dye at 120 V. Gels were transferred to PVDF membranes using the iBlot dry-blotting system (Thermo Fisher Scientific), blocked in 5% non-fat milk powder/PBS (Marvel: Premier Foods, St Albans, UK) and incubated overnight at 4°C in primary antibody dissolved in 1% milk powder/PBS.

iC2C12-DUX4 myoblasts ([@bib11]) were plated at 3000 cells/cm^2^ and DUX4 expression induced by the addition of 500 ng/ml doxycycline hyclate (Thermo Fisher Scientific, J60579) with/without 250 ng/ml Sunitinib for 20 hr. Myoblasts were lysed in RIPA buffer (CST, 9806S) and subjected to three freeze/thaw cycles and the lysate incubated on ice for 20 min and then centrifuged for 20 min at 4°C. Protein concentration was quantified using the DC Protein Assay (Biorad, 500--0116), and 40 µg protein was mixed with 5x Laemmli Buffer, subjected to 10% SDS-PAGE and transferred onto a nitrocellulose membrane (Sigma-Aldrich, WHA10402578). Membranes were blocked in 5% non-fat milk powder in TBS/0.1% Tween 20 (TBS/T) (Sigma-Aldrich, P5927) and incubated with primary antibodies overnight at 4°C. Primary antibodies used were goat anti-RET (C20, Santa Cruz Biotechnology, 1/150), rabbit anti-RET51 (C-19, Santa Cruz Biotechnology, 1/150), rabbit anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (9101, Cell Signalling Technology, 1/1000), rabbit anti-total p44/42 MAPK (Erk1/2) (137F5, Cell Signalling Technology, 1/1000), rabbit anti-phospho-Akt (Ser473) (D9E, Cell Signalling Technology 1/2000), mouse anti-total AKT (40D4, Cell Signalling Technology, 1:2000), mouse anti-DUX4 (9A12, Merck Millipore, 1/1000) and rabbit anti-Caveolin-1 (sc-894, Santa Cruz Biotechnology, 1:500).

Membranes were then washed and protein bands visualised by incubating with horseradish peroxidase (HRP)-conjugated secondary antibodies (GE Healthcare, Chalfont St Giles, UK, Na934V, NA931V, 1/5000) for 1 hr at room temperature. Membrane bound protein was visualised using clarity western ECL substrate (BioRad, 170--5061), and band intensity was quantified with ChemiDoc MP System (BioRad). For iC2C12-DUX4 myoblasts, band intensities were normalised to housekeeping protein Caveolin-1. The ratios of pERK:tERK and pAKT:tAKT in the treated groups were subsequently compared to the ratios in the control group.

Apoptosis assay and FACs {#s4-10}
------------------------

iC2C12-DUX4 myoblasts were induced to express DUX4 with 250 ng/ml or 500 ng/ml doxycycline for 24 hr in the presence of 0, 250 ng/ml or 500 ng/ml Sunitinib malate. Samples were trypsinised and stained with APC-conjugated Annexin V Apoptosis detection kit, according to manufacturer's instructions (BD Biosciences, Franklin Lakes, NJ). Samples were run on a CyAn ADP flow cytometer (Beckman Coulter) and analysed using FlowJo software.

Human myoblast transplantation {#s4-11}
------------------------------

Human cell work in the Tedesco laboratory has been conducted under the approval of the National Health Service Health Research Authority Research Ethics Committee, reference no. 13/LO/1826; IRAS project ID no. 141100. Transplants were performed under UK Home Office Project Licence 70/8566. Immortalised human FSHD clone 54.12 myoblasts were cultured at low density in skeletal muscle cell growth medium (Promocell, C-23160) and separate cohorts either pre-treated 24 hr before transplantation with 250 ng/ml Sunitinib malate or control medium. NOD/scid/γ-chain knockout immunodeficient mice were given an intraperitoneal injection of 20 mg/kg/day Sunitinib malate dissolved in Ca^2+/^Mg^2+^-free PBS (n = 4), while non pre-treated controls received PBS (n = 4). 24 hr later, TA muscles of all eight NOD/scid/γ-chain knockout immunodeficient mice were cryoinjured with a metal probe pre-cooled in liquid nitrogen for 30 s to induce regeneration. TA muscles of the four mice pre-treated with Sunitinib were then injected using a 30G syringe (BD Biosciences) with 1 × 10^6^ 54.12 FSHD myoblasts that had been pre-treated with Sunitinib in vitro, while 1 × 10^6^ non-treated 54.12 FSHD myoblasts per mouse were injected into PBS-treated mice (n = 4) ([@bib31]). Mice grafted with myoblasts pre-treated with Sunitinib then received daily intraperitoneal injections of 20 mg/kg/day Sunitinib malate dissolved in Ca^2+^/Mg^2+^-free PBS, while non pre-treated controls received PBS. Three weeks after transplantation, mice were humanely killed and grafted TA muscles removed and frozen in isopentane cooled in liquid nitrogen. Muscles were mounted using gum tragacanth on cork and serial transverse sections were cut at 8 μm using a Leica CM 1850 UV cryostat (Leica Biosystems, Milton Keynes, UK).

Analysis of cell engraftment {#s4-12}
----------------------------

Cryosections 8 μm thick and spaced 112 μm along the length of the muscle were collected for analysis with human-specific antibodies to measure engraftment of donor myoblasts. Frozen sections were fixed in 4% PFA for 10 min, permeabilised with 0.1% Triton X100/1% BSA (Sigma Aldrich)/PBS and blocked in 10% donkey serum (Dakocytomation) in 0.1% Triton X100/1% BSA/PBS. Cryosections were then incubated with mouse anti-human LAMIN A/C (NCL-LAM, Leica Biosystems) and mouse anti-human SPECTRIN (NCL-SPEC1, Leica Biosystems) to locate engrafted cells and myofibres, together with rabbit anti-mouse Laminin (L9393, Sigma Aldrich) to immunostain extracellular matrix and delimit myofibres. Samples were counterstained with Hoechst to identify total nuclei. The total number of donor-derived LAMIN A/C-positive nuclei within or outside of myofibres, and donor-derived SPECTRIN-positive myofibres were counted in each section along the grafted TA and expressed either as a total per mouse (all sections combined) or an average per section. Quantification was performed blinded with the experimenter unaware of whether the cells were from Sunitinib-treated or control mice.

Statistics {#s4-13}
----------

Data was analysed using either two-tailed Student's *t*-tests, or by statistical models fitted to the data that incorporated random effects due to mouse or between experiment variations (as determined in text). Quasi-Poisson models were used for evaluating the significance of differences in the numbers of cells between conditions and mixed binomial models employed likewise for ratios including the fusion index. Models tested either the linear relationship between a factor and the result, or each combination of factors as an independent parameter. The fusion index was expressed as the ratio of the number of nuclei incorporated into MyHC+ fibres divided by the total number of nuclei in the field of view. Statistical models and analyses were generated using the R programming language ([@bib74]) and Excel.

Image analysis {#s4-14}
--------------

Cell eccentricity analysis was performed on Tubulin immunolabelled cells using a customised R script, written using the EBImage package ([@bib72]) . Images were first pre-processed using a low pass filter to remove low intensity background staining and a high pass filter to exclude non-specific high intensity background based on size and morphology. Cells with overlapping cytoplasm were segregated into independent objects prior to quantification using Voroni segmentation in which DAPI nuclear staining was used as an anchor to define cells; annotated images of segregation were output for visual assessment of correct segregation. The eccentricities of each cell cytoplasm (defined by Tubulin immunolabelling in pre-processed, segregated images) was then computed for each image and the average eccentricity of the frame was obtained, eccentricity computes the cell shape deviation from a circle (1) to a line (0) (Source Code file-Measuring Cell Eccentricity.r).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Discovery of a novel role for Ret tyrosine kinase in muscle stem cells provides a platform for therapy in FSHD\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Janet Rossant as the Senior Editor and Reviewing Editor.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

Summary:

Moyle et al. describe the induction of receptor tyrosine kinase Ret in mouse myoblast cultures following expression of the FSHD causal gene DUX4. The authors investigate the expression pattern of Ret and its co-receptors GRFα1,2,4 during normal myoblast differentiation. They perform loss of function studies showing Ret involvement in myoblast proliferation activation and differentiation inhibition. They further show that Ret down regulation (either by mRNA silencing or kinase inhibitory drugs) rescues the myogenic differentiation defects induced by DUX4.

The study is original, is supported by appropriate experiments and elegantly shows a putative new therapeutic strategy for FSHD with already approved drugs such as Sunitinib. This research is a first step for the identification of therapeutic targets for human FSHD patients.

The reviewers had an extensive discussion and agreed on the potential of this work to provide novel therapy for FSHD. Given the importance of this finding, they strongly felt that there were several key experimental issues that needed to be addressed to ensure the validity of the findings, particularly in terms of in vivo relevance. Listed below are the major experimental issues that they would like to see addressed. In addition, all reviewers expressed concern with the presentation of the data and the statistical analysis. We have tried to define a set of experiments that are achievable in a reasonable time frame and we look forward to receiving a revised manuscript.

Essential revisions:

1\) There hasn\'t been clear evidence that Ret is expressed in mouse muscle progenitors and the papers cited both in the Introduction and Discussion do not support the claim (except for the zebrafish paper Knight et al., 2011). It is essential that authors provide clear evidence that Ret is expressed in vivo at some stage of muscle development and/or homeostasis.

2\) The lack of an animal model for FSHD or DUX4 OE is not a sufficient reason to avoid in vivo experiments. To really test the physiological effect of Ret inhibition or Sunitinib treatment, the authors can use myoblast transfer experiments to assess the in vivo rescue of DUX4 OE cells or FSHD patient cells. These experiments are technically straight-forward and have been used for 10+ years. The authors could trace injected cells by GFP and measure the contribution to muscle regeneration of wild type, DUX4 OE, DUX4 OE treated with siRNA against Ret, and DUX4 OE treated with Sunitinib. The authors can use human myoblasts to really provide the disease relevance of their proposed therapy. These experiments will greatly enhance the significance and impact of this study.

3\) In [Figure 5](#fig5){ref-type="fig"}, DUX4 OE experiments were used to suggest that Ret is a DUX4 target gene. The authors suggest that Ret is an indirect target that is not directly bound by DUX4 homeodomain. However, the expression of the tMALDUX4-VP16 construct did lead to a increase in Ret expression in [Figure 5a](#fig5){ref-type="fig"}. In this construct, VP16 is a strong transcriptional activator and should trigger genes near DUX4 binding sites. Thus, it should be considered that Ret could still be a direct DUX4 homeodomain-binding target. The differences between DUX4 and DUX4c are not well defined and the authors should not interpret their results as such. If they do intend to show that Ret is or isn\'t a direct target of DUX4 DNA-binding, luciferase expression vectors with the proximal promoters of Ret should be used in combination with DUX4 OE to explicitly address this question.

4\) Furthermore, the dominant negative tMALDUX4-ERD construct also increased Ret expression but was not discussed or mentioned in the text. The use of the Engrailed repressor domain should have shut down the DUX4 pathway, yet Ret is still upregulated. The authors should discuss this phenomenon. Is this the reason why the authors do not think that Ret is a direct target of DUX4?

5\) Caspase 3/7 is not an accurate read out of cell death in the myogenic system. Previous studies have suggested the participation of capspases in the differentiation program. So the proportion of caspase 3/7 staining is affected by changes in differentiation. The authors should perform alternative measurements of cell viability (alamar blue, propidium iodide, etc.).

6\) The authors take a candidate approach to identify RTK inhibitors using phenotypic readouts of cell proliferation and differentiation. However, to demonstrate the pharmacological inhibition of Ret, the authors should provide a read out of Ret inhibition by Sunitinib and other small molecules using a downstream signalling effector.

7\) There seems to be a difference in the function of Ret in wild type myoblasts compared to its function in DUX4 OE or FSHD cells. Knockdown experiments in wild type cells decreased their proliferation, whereas Ret OE led to higher myoblast proliferation. However, in DUX4 OE and FSHD cells Ret inhibition through siRNA knockdown or Sunitinib treatment, proliferation of myoblasts did not change accordingly. The authors should discuss this difference. Are differences in the basal rates of proliferation in DUX4 OE and FSHD cells affected? Do these changes match the predicted change with Ret OE? These differences should be discussed further in the manuscript.

8\) Statistics should be revised throughout the manuscript. Authors are frequently using paired t-test approach (e.g., [Figure 1](#fig1){ref-type="fig"}) although there are no paired data. They should consider either simple t-test or even one way ANOVA followed by multiple t-tests. Significance asterisks seem to be random as they are presented for only a subset of bars within graphs although clearly other bars are (appear to be) also significantly different from the controls (e.g.,, [Figures 4](#fig4){ref-type="fig"}).

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for Facioscapulohumeral muscular dystrophy\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Janet Rossant and three reviewers.

The authors have correctly addressed most of the reviewers\' critiques and have accordingly improved the clarity of their manuscript. The data presented about an unexpected pathway contributing to DUX4 pathological activity are really novel and exciting. RET / ERK involvement in FSHD and the possibility of targeting their pathway by a drug approved in cancer will most probably open new perspectives in the therapeutic approaches of FSHD. We are glad to see that the authors were able to perform myoblast engraftment assays with the human FSHD samples and demonstrate the efficacy of Sunitinib in vivo. However, there are still some mechanistic concerns, especially in regard to the action of Sunitinib.

These concerns can be addressed by modifying some of the claims of the paper, without new experiments.

1\) A request for clarification at the end of the Discussion: If indeed ERK induces proliferation and inhibits differentiation, ERK inhibition by Sunitinib in DUX4-expressing cells is expected to do the opposite i.e. decrease proliferation besides increasing differentiation. Why is that decreased proliferation presented as an unexpected observation? What are the Authors suggesting as \"another mechanism\"?

2\) While ChIP qPCR is a method to determine if DUX4 is a direct activator of Ret, the experiment lacks proper controls. There is no positive control to confirm that the ChIP experiment is working. There is also the possibility that the predicted site does not contain the DUX4 binding site.

Moreover, there is a rather glancing discussion on why the tMALDUX4-ERD construct also induced Ret expression. The Discussion will benefit from more critical perspectives of the results.

3\) The identification of pERK1/2 as a readout of Ret activity is also weakly supported. pERK1/2 is not upregulated with DUX4 overexpression, therefore is not likely a Ret target. The decrease in ERK1/2 with Sunitinib treatment yields more questions than answers. It would suggest that Sunitinib is acting on ERK phosphorylation and not Ret activity.

While it can be argued that Sunitinib only inhibits ERK when DUX4 is expressed, it could also be due to the co-treatment with Doxycyclin.

10.7554/eLife.11405.029

Author response

*1) There hasn\'t been clear evidence that Ret is expressed in mouse muscle progenitors and the papers cited both in the Introduction and Discussion do not support the claim (except for the zebrafish paper Knight et al., 2011). It is essential that authors provide clear evidence that Ret is expressed* in vivo *at some stage of muscle development and/or homeostasis.*

We show that Ret is expressed by immunostaining in activated murine satellite cells associated with myofibres ex vivo ([Figure 1](#fig1){ref-type="fig"}). That gene expression is modulated in expanded satellite cells during myogenic differentiation using by RT-qPCR ([Figure 1](#fig1){ref-type="fig"}). Furthermore, RET can be detected by RT-qPCR in human satellite cell-derived primary myoblasts ([Figure 2](#fig2){ref-type="fig"}) and C2 cells ([Figure 6](#fig6){ref-type="fig"}).

We have tried using the commercially available antibodies on regenerating mouse muscle sections and embryos, but the immunostaining is not convincing, in contrast to immunolabeling cells ex-vivo. We have augmented the supporting literature showing Ret in muscle in the Introduction and Discussion and hope that we have now provided sufficient data/supporting evidence.

*2) The lack of an animal model for FSHD or DUX4 OE is not a sufficient reason to avoid* in vivo *experiments. To really test the physiological effect of Ret inhibition or Sunitinib treatment, the authors can use myoblast transfer experiments to assess the* in vivo *rescue of DUX4 OE cells or FSHD patient cells. These experiments are technically straight-forward and have been used for 10+ years. The authors could trace injected cells by GFP and measure the contribution to muscle regeneration of wild type, DUX4 OE, DUX4 OE treated with siRNA against Ret, and DUX4 OE treated with Sunitinib. The authors can use human myoblasts to really provide the disease relevance of their proposed therapy. These experiments will greatly enhance the significance and impact of this study.*

We had considered testing Sunitinib in an in vivo model for FSHD but it is not a particularly straightforward experiment, partly because of the lack of a suitable model (Lek, A., et al., Emerging preclinical animal models for FSHD. Trends Mol Med, 2015. 21(5): p. 295-306).

We therefore decided to use the immortalized human FSHD myoblast line 54.12 for grafting as this cell line has previously been shown to engraft into mouse muscle. Using this cell line we have been able to show that Sunitinib could improve proliferation/differentiation in vitro ([Figures 10](#fig10){ref-type="fig"}--[11](#fig11){ref-type="fig"}). We tried two models, transplantation into Zebrafish and into immuno-compromised mice. Pilot experiments of grafting 54.12 and 54.6 into Zebrafish indicated that it would require extensive optimization, hence we concentrated on using mouse as the host.

Cryoinjured Tibialis anterior muscles of immunodeficient, NOD/scid/γ chain knockout mice were grafted with 1x106 54.12 FSHD myoblasts, and mice given daily doses of Sunitinib or PBS for 3 weeks, and the muscles removed for analysis. Serial cryosections throughout the length of the muscles were immunostained to measure engraftment efficiency using human-specific antibodies against LAMIN A/C to detect human cells/myonuclei and SPECTRIN to measure myogenic differentiation of donor myoblasts. There was a significant increase in both mean number of LAMIN A/C positive cells in mice treated with Sunitinib compared to controls and number of LAMIN A/C positive cells located within myofibres (myonuclei). Sunitinib treatment also increased the number of SPECTRIN positive myofibres and SPECTRIN-positive/LAMIN A/C-positive myofibres. A more powerful statistical analysis that accounted for biological variation, highlighted the effectiveness of Sunitinib in improving FSHD cell engraftment. In summary, Sunitinib treatment improves the regenerative capacity of FSHD myoblasts by increasing engraftment of cells, and increasing their capacity for myogenic differentiation into SPECTRIN-positive myofibres. This data is now included as [Figure 12](#fig12){ref-type="fig"} in the revised manuscript.

3\) In [Figure 5](#fig5){ref-type="fig"}, DUX4 OE experiments were used to suggest that Ret is a DUX4 target gene. The authors suggest that Ret is an indirect target that is not directly bound by DUX4 homeodomain. However, the expression of the tMALDUX4-VP16 construct did lead to a increase in Ret expression in [Figure 5a](#fig5){ref-type="fig"}. In this construct, VP16 is a strong transcriptional activator and should trigger genes near DUX4 binding sites. Thus, it should be considered that Ret could still be a direct DUX4 homeodomain-binding target. The differences between DUX4 and DUX4c are not well defined and the authors should not interpret their results as such. If they do intend to show that Ret is or isn\'t a direct target of DUX4 DNA-binding, luciferase expression vectors with the proximal promoters of Ret should be used in combination with DUX4 OE to explicitly address this question.

To determine if Ret is a direct target of DUX4, we performed ChIP using C2C12 myoblasts transduced with a truncated DUX4 version that has lower toxicity than full length DUX4, but still contains the DNA binding homeodomains (tMALDUX4-V5). ChIP-qPCR primers were designed around a potential homeodomain binding region approximately 850bp upstream of the transcriptional start site of Ret. There was no significant difference in the enrichment of the tMALDUX4-V5 compared to the IgG control, indicating that DUX4 did not directly bind to this region of the Ret promoter. This data is presented in [Figures 6H and I](#fig6){ref-type="fig"} of the revised manuscript.

Since the dominant negative tMALDUX4-ERD construct also increased Ret expression, and we were unable to show DUX4 binding to the Ret promoter by ChIP, this combined evidence indicated that Ret was not a direct DUX4 target. Thus we felt that obtaining and optimising RET promoter constructs would not be helpful. We have amended the Discussion to include these points.

*4) Furthermore, the dominant negative tMALDUX4-ERD construct also increased Ret expression but was not discussed or mentioned in the text. The use of the Engrailed repressor domain should have shut down the DUX4 pathway, yet Ret is still upregulated. The authors should discuss this phenomenon. Is this the reason why the authors do not think that Ret is a direct target of DUX4?*

That is correct, combined with the ChIP experiment, as detailed in the response above. We have now discussed the implications of these observations in the manuscript.

*5) Caspase 3/7 is not an accurate read out of cell death in the myogenic system. Previous studies have suggested the participation of capspases in the differentiation program. So the proportion of caspase 3/7 staining is affected by changes in differentiation. The authors should perform alternative measurements of cell viability (alamar blue, propidium iodide, etc.).*

We used the Caspase 3/7 release assay in proliferating satellite cell-derived myoblasts in proliferation medium. Furthermore, overexpression of RET proteins does not induce myogenic differentiation in proliferating myoblasts. Thus, any role of Caspase in myogenic differentiation should not interfere with this apoptosis assay to determine if Ret affects apoptosis. However, we have also now measured Annexin V and π in iC2C12-DUX4 myoblasts induced with varying concentrations of Doxycycline and treated with 250ng/ml Sunitinib to measure both apoptosis in response to DUX4 and effects of Sunitinib on DUX4-induced apoptosis. While DUX4 expression increased the proportion of iDUX4-C2C12 myoblasts gated as apoptotic (AV+/PI-, AV-/PI+, AV+/PI+), treatment with Sunitinib had no significant effect. These data have been included as [Figure 9](#fig9){ref-type="fig"}.

*6) The authors take a candidate approach to identify RTK inhibitors using phenotypic readouts of cell proliferation and differentiation. However, to demonstrate the pharmacological inhibition of Ret, the authors should provide a read out of Ret inhibition by Sunitinib and other small molecules using a downstream signalling effector.*

We agree with the reviewers' suggestion. As we have described, constitutively active RET suppressed myogenic differentiation in C2C12 myoblasts and this provides a phenotypic readout of Sunitinib efficacy. To show the pharmacological inhibition of Ret by Sunitinib in myoblasts, we have also assayed phosphorylated ERK and AKT: well characterized downstream effectors of Ret (e.g., Airaksinen and Saarma. Nat Rev Neurosci, 2002. 3(5): p. 383-94). We used iC2C12-DUX4 myoblasts to express DUX4, and measured phosphorylated and total ERK and AKT by quantifying immunoblots. We found that phosphorylated ERK is decreased upon treatment with Sunitinib in DUX4 expressing myoblasts. This is now included as [Figure 8](#fig8){ref-type="fig"}.

*7) There seems to be a difference in the function of Ret in wild type myoblasts compared to its function in DUX4 OE or FSHD cells. Knockdown experiments in wild type cells decreased their proliferation, whereas Ret OE led to higher myoblast proliferation. However, in DUX4 OE and FSHD cells Ret inhibition through siRNA knockdown or Sunitinib treatment, proliferation of myoblasts did not change accordingly. The authors should discuss this difference. Are differences in the basal rates of proliferation in DUX4 OE and FSHD cells affected? Do these changes match the predicted change with Ret OE? These differences should be discussed further in the manuscript.*

The Discussion has been amended to include this point.

8\) Statistics should be revised throughout the manuscript. Authors are frequently using paired t-test approach (e.g., [Figure 1](#fig1){ref-type="fig"}) although there are no paired data. They should consider either simple t-test or even one way ANOVA followed by multiple t-tests. Significance asterisks seem to be random as they are presented for only a subset of bars within graphs although clearly other bars are (appear to be) also significantly different from the controls (e.g., [Figures 4](#fig4){ref-type="fig"}).

We have adopted a standardized approach to statistical testing throughout the manuscript.

In cases in which we have made a pairwise comparison between an experimental manipulation and the corresponding control, we have used a t-test assuming a normal distribution of data. When comparing the effects of gene expression or drug application on cultured cells, we have used an unpaired t-test to test significance. When comparing cells derived from the same mouse that have been exposed to different conditions, we have used paired t-tests to test for significance. This is appropriate, provided the pairwise comparisons are made considering cells from the same mouse. For analysis of experiments with multiple parameters to consider, such as origin of cells and effects of a drug, we have used logistical models. These models have allowed us to dissect significant changes caused by single variables in the context of large variation due to other variables. We have better defined which tests are used in the revised manuscript and carefully checked that significant differences are indicated with an asterisk for all t-tests.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

*These concerns can be addressed by modifying some of the claims of the paper, without new experiments.*

*1) A request for clarification at the end of the Discussion: If indeed ERK induces proliferation and inhibits differentiation, ERK inhibition by Sunitinib in DUX4-expressing cells is expected to do the opposite i.e. decrease proliferation besides increasing differentiation. Why is that decreased proliferation presented as an unexpected observation? What are the Authors suggesting as \"another mechanism\"?*

We have modified the Discussion to remove these ambiguities.

*2) While ChIP qPCR is a method to determine if DUX4 is a direct activator of Ret, the experiment lacks proper controls. There is no positive control to confirm that the ChIP experiment is working. There is also the possibility that the predicted site does not contain the DUX4 binding site.*

*Moreover, there is a rather glancing discussion on why the tMALDUX4-ERD construct also induced Ret expression. The Discussion will benefit from more critical perspectives of the results.*

We have re-evaluated the ChIP experimental data ([Figure 6](#fig6){ref-type="fig"}) in light of the recent paper by the Kyba group (Choi et al. (2016) NAR 44, 5161-73) which provides a second ChIP-seq dataset and refines the DUX4 consensus binding site. Since the Ret promoter region does not contain this refined DUX4 consensus site and we could find no ChIP-seq peaks within 15 kb of the Ret TSS, we have now decided to remove our ChIP data. We discuss the implications of these papers for Ret being a direct DUX4 target gene in detail in the revised Discussion. We have also included more clarification about the tMALDUX4-ERD observation.

*3) The identification of pERK1/2 as a readout of Ret activity is also weakly supported. pERK1/2 is not upregulated with DUX4 overexpression, therefore is not likely a Ret target. The decrease in ERK1/2 with Sunitinib treatment yields more questions than answers. It would suggest that Sunitinib is acting on ERK phosphorylation and not Ret activity.*

*While it can be argued that Sunitinib only inhibits ERK when DUX4 is expressed, it could also be due to the co-treatment with Doxycyclin.*

DUX4 up-regulates Ret, and Sunitinib can clearly rescue the differentiation block caused by CA-RET51 in C2C12 myoblasts. Furthermore, ERK1/2 phosphorylation was only inhibited by Sunitinib in DUX4-expressing iC2C12-DUX4 myoblasts. Thus we feel that Sunitinib acting via Ret to inhibit phopsphorylation of ERK is one valid interpretation of the data. However, we have modified the Discussion to accommodate the caveat that Sunitinib could be acting on ERK phosphorylation and not Ret activity. While the observations could also be due to the co-treatment with Doxycyclin, we feel that this is unlikely, as we did not see any effects on ERK phosphorylation with Doxycyclin treatment alone ([Figure 8H--J](#fig8){ref-type="fig"}).
